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ABSTRACT 
 
IRON STATUS, INFLAMMATION AND ANEMIA  
IN BANGLADESHI WOMEN EXPOSED TO ARSENIC  
 
FEBRUARY 2011 
JOYCELYN FARAJ, B.S. UNIVERSITY OF MASSACHUSETTS AMHERST 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Dr. Alayne Ronnenberg 
 
Iron depletion is the most common nutrient deficiency worldwide and is the 
leading cause of anemia. The prevalence of anemia in Bangladeshi women has 
been estimated by others at 45%, but the prevalence of iron depletion (ID) and 
iron deficiency anemia (IDA) in these women remains unknown. Chronic arsenic 
(As) exposure, which is a major public health problem in Bangladesh, is 
associated with increased risk of anemia.  Arsenic exposure also triggers 
inflammatory responses that alter iron parameters, including serum ferritin, 
rendering IDA assessment more challenging. We assessed the prevalence of ID 
and IDA in 147 Bangladeshi women, ages 18-33 years, who participated in a 
larger study of arsenic exposure and skin lesions. The current study includes 75 
women with skin lesions (cases) and 72 women without lesions (controls). Blood 
samples, anthropometric, sociodemographic and dietary data were collected at 
enrollment. Hb, ferritin and hs-c-reactive protein (CRP) were measured in serum. 
Overall, the prevalence of anemia (Hb < 120 g/L) was 18%.  Although the 
prevalence of ID (ferritin ≤12mcg/L) did not differ between cases and controls, 
 vii 
 
the prevalence of anemia  was almost three times higher among women with 
arsenic-related skin lesions compared with controls (25% vs 10%, respectively; 
p=0.02). Of the women with anemia, 27% (N=7) also had ID (Hb<120g/L and 
ferritin ≤12 mcg/L), indicating IDA. Women with normal iron status had double the 
concentration of toenail arsenic compared to iron-depleted women (2.9 vs 1.4 µg 
As/g toenail; p=0.00). In addition, the arsenic concentration of their water source 
was three-times higher than that of iron-depleted women (18.8 vs 6.2 µg As/L; 
p=0.03). Mean CRP was higher in cases than controls (p=0.04) as well as in 
those with serum ferritin >12mcg/L compared to those who were iron deplete 
(p=0.02). In multivariable logistic regression,. the risk of ID was 84% lower in 
women ages 29-33 compared to women ages 18-22 (OR=0.16, 95% CI=0.04, 
0.56); every 1µg increase in toenail As level was associated with a 45% lower d 
risk of ID (OR=0.55 , 95% CI=0.33, 0.94).The presence of inflammation 
decreased the odds of being classified as  ID by 80% (OR=0.20, 95% CI=0.04, 
0.96).  Much of the anemia in this cohort appears unrelated to iron deficiency, but 
could be linked to other nutrients, such as folate and vitamin B12, which are 
involved in both hematopoiesis and arsenic metabolism. It is possible that 
arsenic exposure in this cohort compromised folate and vitamin B12 status. 
Because these vitamins are also important during pregnancy, additional studies 
are needed to assess B-vitamin status in arsenic-exposed women and to 
determine whether B-vitamin status influences reproductive outcomes in these 
women. 
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CHAPTER 1 
 
INTRODUCTION 
 
Iron deficiency is one of the most common nutrient deficiencies, affecting 2 billion 
people worldwide.  It is also the leading cause of anemia (WHO, 2005), and 
therefore contributes to disability and death. In developed areas of the world, 
only about 8% of the population has anemia, but in developing regions, the 
percentage of anemia averages 36% (Crichton, 2006).  Estimates of the national 
prevalence of anemia in Bangladesh have remained constant at 74% for the past 
30 years; this high rate of anemia is a major public health concern for 
Bangladesh, causing a loss of productivity totaling 1.9% of the national gross 
domestic product (Ahmed, 2000).   
 
According to the World Health Organization (WHO), approximately 50% of all 
cases of anemia, defined as hemoglobin concentration less than 120 g/L in non-
pregnant adults, can generally be attributed to iron deficiency (WHO, 2005), and 
the leading cause of iron deficiency is dietary inadequacy.  In women of 
reproductive age, menstrual losses also contribute considerably to iron 
deficiency.  In developing countries, such as Bangladesh, parasitic infections 
such as malaria and hookworm also contribute to iron deficiency (WHO, 2005). In 
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addition to iron, deficiencies of other micronutrients, including folate and vitamins 
B12, B6, and A also contribute to anemia (WHO, 2005; Ronnenberg et al., 2000). 
 
Iron deficiency and anemia hinder normal human functions in all age groups, 
reducing work performance (Haas JD, 2001). Maternal iron deficiency can also 
result in adverse pregnancy outcomes, including preterm delivery and lower birth 
weight (Allen, 2000; Ronnenberg et al, 2004).  Impaired immune responses, 
gastrointestinal abnormalities, changes in the hair and nails, impaired 
thermogenesis, altered thyroid metabolism, and changes in catecholamine 
turnover have also been observed in subjects with iron deficiency (Crichton, 
2006). 
 
In addition to its high prevalence of anemia, Bangladesh also faces a major 
health challenge: chronic arsenic poisoning.  An estimated 57 million 
Bangladeshis are chronically exposed to arsenic via drinking water (British 
Geological Survey, 2001). The mechanism of arsenic toxicity remains largely 
unknown; however, there is evidence that arsenic poisoning may influence 
hematological variables (Hernandez-Zavala et al., 1999; Szymanska-Chabowska 
et al. 2002; Tchounwou et al, 2003).  In vivo and in vitro studies have shown that 
arsenic can bind to animal and human hemoglobin (Delnomdedieu et al. 1995; 
Lu et al, 2004; Winski & Carter, 1995) and can alter heme metabolism, 
hemoglobin concentration and red blood cell morphology (Delnomdedieu et al, 
1994; Flora et al 2005; Kannan et al, 2001).  Other studies found that chronic 
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ingestion of arsenic-contaminated drinking water altered heme metabolism by 
increasing the activity of two key enzymes in heme metabolism, porphobilinogen 
deaminase and uroporphyrinogen decarboxylase, in peripheral red blood cells 
and increasing total urinary excretion of porphyrins (Hernandez-Zavala et al. 
1999).  
 
The effects of chronic arsenic toxicity on the heme system and on iron status 
remain largely unexplored.  The main goal of this research project is to study the 
relationship between biomarkers of iron status, inflammation, anemia, and 
arsenic-associated skin lesions in women of reproductive age from Bangladesh.   
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CHAPTER 2 
 
IRON 
 
2.1 Introduction and Biological Functions 
Iron (Fe) is an essential nutrient, for numerous biological processes, including 
electron transfer reactions and substrate oxidation-reduction, regulation of gene 
expression, binding and transport of oxygen, and regulation of cell growth and 
differentiation (Beard, 2006)   Although essential, iron can also be a potential 
toxicant to cells, hence its bioavailability is highly regulated by various complex 
mechanisms. The regulating mechanisms used by the body include control of 
dietary iron absorption, iron entry into cells, intracellular storage of iron as ferritin, 
release of iron from cells, and sequestering of free iron by iron binding proteins. 
 
Iron exists in two oxidation states in aqueous solution, ferrous iron (Fe2+) and 
ferric iron (Fe3+), and it can change from one state to the other by the subtraction 
or addition of an electron.  Certain reducing agents, such as vitamin C (ascorbic 
acid) can convert ferric iron to ferrous iron.  Exposure to oxygen can also convert 
ferrous iron to its ferric form.  This inter-conversion of oxidation states is essential 
for electron transfer reactions as well as for reversible binding to ligands.  
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Preferred ligands of iron include oxygen, nitrogen and sulfur atoms (Beard, 
2006).  
 
 2.1.1 Iron-Containing Proteins 
Most of the iron in plant or animal cells is stored within large complex proteins 
such as hemosiderin or ferritin.  The remainder of the iron is either contained as 
an essential functional component within proteins and enzymes, or in iron 
transport proteins (Beard, 2006).  The main categories of iron-containing proteins 
in mammals include heme-containing hemoproteins (e.g., hemoglobin, 
myoglobin, and cytochromes); iron-sulfur cluster-containing enzymes (such as 
flavoproteins); iron storage proteins (e.g., ferritin); iron transport proteins (e.g., 
transferrin, lactoferrin); and iron-dependent enzymes (Beard 2006).   
 
Heme-proteins: The key function of iron is to move oxygen from the environment 
to terminal oxidases.  Oxygen is bound to iron in the porphyrin ring of the heme 
moiety in hemoglobin, found within red blood cells (RBC), or in myoglobin, the 
facilitator of oxygen diffusion in tissues (Beard, 2006).  Hemoglobin (Hb, MW 64 
KDaltons) is a tetrameric protein with two pairs of identical subunits (alpha-2 and 
beta-2).  Each of the subunits has one heme (iron-protoporphyrin-IX) prosthetic 
group whose ferrous iron reversibly binds dioxygen.  The four subunits of Hb are 
not covalently attached, but they do react cooperatively with dioxygen, with 
specific modulation by pH, carbon dioxide pressure, organic phosphatases, and 
temperature, all of which determine the efficiency of oxygen transfer from the 
 6 
 
Figure 2.1:  Hemoglobin molecule. Iron in heme group binds to the center 
of the alpha and beta chains of hemoglobin. 
 
Sylvia S. Mader, Inquiry into Life, 8
th
 edition. The McGraw-Hill Companies © 1997 
alveoli capillary interface in the lungs to the red blood cell/capillary tissue 
interface in peripheral tissues (Beard, 2006).  Decreasing pH causes an allosteric 
effect (Bohr effect) that decreases the binding affinity of heme iron for dioxygen, 
thus improving the release of oxygen in tissues where the pH is lower and the 
CO2 pressure is higher than in arterial blood (Beard, 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
Fe-S Proteins:  Another group of iron-containing proteins are iron-sulfur cluster 
proteins.  These proteins contain iron-sulfur centers with equal numbers of iron 
and sulfide ions (2Fe-2S and 4Fe-4S).  They are usually involved in electron 
transfer reactions, and include proteins of the mitochondrial electron transport 
chain as well as various mini-electron transport systems (Beard, 2006).  Some 
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Fe-S proteins also have functions in catalysis and biological sensors for iron, 
oxygen, and superoxide (Flint and Allen, 1996).  
 
Fe Storage Proteins:  The proteins involved in iron storage are ferritin and 
hemosiderin.  These proteins play a key role in cellular ―housekeeping‖ in most 
cells by sequestering free iron, thereby preventing the unwanted effects of iron-
catalyzed free radical generation or iron oxidation and precipitation.  In addition, 
these proteins serve as an iron reservoir in specialized cells involved in iron 
metabolism, such as macrophages of the reticuloendothelial system and 
parenchymal cells of the liver (Beard, 2006).  
 
The apo-ferritin (iron-free) molecule has a molecular mass of approximately 500 
kDaltons, and can hold up to 4,500 iron atoms in a non-toxic, water-soluble, yet 
bioavailable form (Crichton, 2006).  The mechanism of iron release from the 
ferritin molecules is not well understood, but appears to involve reducing 
conditions and a more acidic pH (Crichton, 2006).  The iron-storage protein 
ferritin is primarily an intracellular protein; however, minor amounts of ferritin are 
present in the circulation in proportion to iron stores.  Plasma ferritin, unlike 
intracellular ferritin, is glycosylated and relatively iron-poor.  Ferritin is a positive 
acute-phase reactant, and as such is elevated in states of inflammation.  
 
Ferritin is a soluble protein, but can be degraded to insoluble hemosiderin, which 
accumulates in lysosomes and also acts as a storage form of iron that is 
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available for protein and heme synthesis (Ward et al, 1994). Hemosiderin is 
insoluble and particulate, with a granular appearance when stained, as opposed 
to ferritin, which is soluble and has a non-granular light blue staining of the 
hepatocytes or macrophage cytoplasm (Batts, 2007).  Increased hemosiderin 
deposition in the liver and in biliary epithelium is observed mainly in conditions of 
iron overload (i.e., hereditary hemochromatosis and transfusion-dependent 
hemoglobinopathies) (Crichton, 2006).   
 
Fe Transport Proteins:  Transferrin is the major plasma protein involved in iron 
transport throughout most of the extracellular fluids of the body, with a 
continuous circulation from the blood to interstitial fluid.  It is a glycoprotein, 
synthesized mainly in the liver, containing two iron-binding sites, encoded on 
chromosome 3 (Crichton, 2006).  The protein is composed of a single 
polypeptide chain of approximately 680 amino-acid residues, with two similar 
amino- and carboxy- terminal lobes, each organized into two distinct domains; 
each lobe contains an iron-binding site.  Transferrin‘s affinity for Fe3+ is high (Kd 
10-19 to 10-20 M).  There are six atoms required for iron binding, four of which are 
provided by the protein (one aspartate, one histidine, and two tyrosine residues) 
and the remaining two are provided by a carbonate anion, which is essential for 
iron binding (Crichton, 2006).  Conformational changes take place during the 
binding and release of iron.  When the iron-binding site is free, the protein adopts 
an open conformation, and when iron is bound in the presence of the carbonate 
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anion, the transferrin iron binding sites take up a pincer-like closed position 
around the iron atom (Crichton, 2006).  
 
2.2 Iron Absorption 
 
Intestinal iron absorption depends on three conditions: the iron content of the 
diet, the bioavailability of the dietary iron, and the capacity of the mucosal cells to 
absorb the iron (Crichton, 2006).  There are two kinds of dietary iron: heme and 
non-heme or inorganic iron.  Iron-replete persons will absorb proportionally less 
of any amount of non-heme iron consumed than will those who are iron-deficient. 
This type of selective absorption is the main mechanism by which iron is 
regulated in the human body (Beard, 2006).  The recommended dietary intake of 
iron for adults is around 13-18 mg per day, out of which only 1 mg is absorbed.  
Even in iron deficiency, absorption is only increased to approximately 2-4 
mg/day, and in iron overload, it is reduced to 0.5 mg/day (Miret, 2003).  
 
2.2.1 Non-Heme Iron Absorption 
 
Most dietary iron occurs in the non-heme form, which is present in foods as 
either the reduced ferrous (Fe2+) or the oxidized ferric (Fe3+) form. Non-heme iron 
is found in both plants and animal sources; in plants, it is present in three major 
forms: as metalloproteins (plant ferritin), as soluble iron in the sap of xylem, 
phloem and plant vacuoles, and as nonfunctional iron complexed with plant 
structural or storage components, primarily in the form of phytates.  A large 
amount of dietary non-heme iron is present as contaminant ferric oxides and 
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hydroxides.  In animal-derived foods, iron can be found in meat products as 
ferritin and hemosiderin; in egg yolk, it is bound to the phosphoprotein 
phosphovitin, and in milk it is bound to lactoferrin or associated with fat globule 
membranes and low molecular weight compounds (such as citrate) (Crichton, 
2006).   
 
Upon entering the stomach, non-heme iron is acted upon by gastric juices 
containing pepsin and hydrochloric acid, which reduce ferric to ferrous iron, 
making it more bioavailable.  Iron is better absorbed in the upper small intestine, 
mainly in the duodenum, where the low pH enhances its solubility (Miret, 2003).  
Under normal physiological conditions (i.e. normal pH and presence of oxygen), 
ferrous iron is quickly oxidized to ferric iron and precipitates as ferric 
oxyhydroxides; precipitation  tends to occur in the luminal contents of the 
gastrointestinal tract as the pH increases.  However, the slightly acidic 
microclimate in the duodenal surface (pH 6-6.5) helps maintain significant levels 
of iron in the ferrous form, as does cell surface reductase activity.  This 
microclimate also provides a proton gradient directed toward the cell interior, 
creating an additional driving force for iron uptake into the enterocyte (O‘Riordan 
et al., 1995). 
 
Non-heme iron is thought to be taken across the brush-border membrane of the 
enterocyte after being reduced from ferric to ferrous iron by an apical or brush 
border ferric reductase called duodenal cytochrome b (DCYTB). Once iron is 
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reduced by ascorbic acid or other reducing agents, ferrous iron can be 
transported by the divalent metal ion transporter (DMT1), which transports only 
ferrous iron (Gunshin, Mackenzie et al, 1997).  Iron deficiency and hypoxia  
stimulate duodenal expression of DMT1, DCTYB and ferroportin (an iron 
exporter), leading to increased iron absorption (Zimmermann and Huller, 2007). 
 
2.2.2 Heme Iron Absorption 
 
Hemoglobin and myoglobin from animal foods are the main protein sources for 
heme iron. Heme iron has a high intrinsic bioavailability and is soluble in an alkali 
environment.  Heme is released from hemoglobin during digestion in the small 
intestine and is thought to then bind to a specific receptor on the enterocyte, after 
which it is internalized via endocytosis (Crichton, 2006). Absorbed heme is acted 
upon by heme oxygenase 1 (HOX1) in the enterocyte to release iron to the 
soluble cytoplasmic pool (Beard, 2006).   Release of iron from heme by HOX1 
appears to be the rate-limiting step in heme-iron absorption (Crichton, 2006). 
 
 12 
 
Figure 2.2:  Transport of heme and non-heme iron through enterocyte 
Zimmermann MB & Hurrell RF. Nutritional Iron Deficiency. Lancet. 2007 Aug 11;370(9586):511-20  
 
 
 
2.3 Iron Stores and Mobilization 
 
Once inside the enterocyte, iron from both heme and non-heme sources enters a 
low molecular-weight pool, where it can either be stored in the mucosal cell as 
ferritin or it can be transported across the basolateral membrane into the plasma 
by the transmembrane protein ferroportin 1, also known as IREG-1 (Crichton, 
2006).  This pool of intracellular transit iron is referred to as ―labile iron‖.  
 
In order for absorbed iron to be incorporated into apotransferrin, it needs to be 
oxidized to its ferric form either by hephaestin (a membrane bound protein) or by 
ceruloplasmin (the main copper-containing protein in the serum) (Crichton, 
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2006).  The main route of iron delivery to cells is mediated by the transferrin 
receptor on the cell surface, whose concentration is directly influenced by cellular 
iron status. The delivery of iron to cells via transferrin is dependent on the 
expression of transferrin receptors, which have a high affinity for saturated 
transferrin (Crichton, 2006). 
 
Regulation of transferrin receptor synthesis is mediated by iron-response 
proteins (IRPs) binding to mRNA iron- response elements (IREs) (Casey, Hentze 
et al, 1988).  As the cellular pool of low-molecular-weight iron decreases, there is 
an up-regulation of iron uptake into cells, and a down-regulation of the synthesis 
of iron storage proteins; this mechanism is exerted via the action of iron 
regulatory proteins (IRP-1, IRP-2) that regulate transferrin receptor and ferritin 
mRNA translation (Beard, 2006). 
 
2.4 Iron Homeostasis 
 
The mean serum iron level is approximately 20 micromol/L, and the normal 
plasma transferrin concentration is approximately 30 micromol/L. Each transferrin 
has two slots for iron; consequently, transferrin is normally about a third 
saturated with iron (Crichton, 2006). Plasma transferrin typically carries about 3 
mg of iron. A decline in the iron storage pools to 15% saturation of iron binding 
sites results in less than adequate iron being delivered to essential body iron 
proteins (Beard, 2006). 
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Figure 2.3:  Iron stores and mobilization throughout the body.  
 
Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341(26):1986-95. 
 
 
 
 
 
 
The major pathway of iron turnover involves the release of iron from the 
hemoglobin of destroyed erythrocytes, followed by degradation of myoglobin and 
iron-containing enzymes (Sherwood et al, 1998).  About 85-90% of the body iron 
stores are found in the erythroid mass.  Red blood cells, which have an average 
lifetime of 120 days, contain about 80% of the body‘s functional iron (Crichton, 
2006).  The formation of RBC requires about 30 mg of iron daily, which is 
balanced by an equal flux of iron from the breakdown of senescent red blood 
cells by the reticuloendothelial cells in the spleen and Kupffer cells (Miret, 2003).  
About 85% of iron derived from hemoglobin degradation is re-released to the 
body in the form of iron bound to transferrin or ferritin (Crichton, 2006).  
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In the erythroid iron cycle, senescent red blood cells are broken down mainly by 
macrophages in the spleen, and the extracted iron is returned to the circulation 
where it binds to transferrin.  Plasma transferrin then binds to specific transferrin 
receptors (TfRs) on surface of cells.  The number of transferrin receptors on a 
cell‘s surface reflects the cell‘s iron requirements; the cells that require the most 
iron are the nucleated red cell precursors in the bone marrow that synthesize 
hemoglobin: these have the greatest number of receptors (Baker, 1994). 
Transferrin binds to the receptors on these erythroid precursors in the bone 
marrow, and the cycle is completed when new RBCs enter the circulation in the 
following 7-10 days. Iron absorption increases during enhanced erythropoietic 
activity. The rate of erythropoiesis is regulated by the concentration of 
erythropoietin, produced by the kidneys (Crichton, 2006).  Iron deficiency 
increases iron transfer through the cycle to by stimulating increased ferroportin 
expression on macrophages, hepatic synthesis of transferrin, and expression of 
transferrin receptor (TfR1) in the bone marrow and other tissues (Zimmermann 
and Huller, 2007). 
 
Two essential regulators of iron absorption recently identified are hepcidin, an 
antimicrobial peptide synthesized by the liver (Ganz, 2003), and hemojuvelin, a 
426-residue protein that shows homology to a molecule involved in axonal 
guidance in the central nervous system (Papanikolaou et al., 2004). Hepcidin is 
an antimicrobial peptide that was shown to be involved in regulation of iron 
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homeostasis in animal studies (Nicolas et al., 2001; Pigeon et al., 2001).  The 
mRNA for murine hepcidin appears to be upregulated during parenteral or dietary 
iron overload as well as during immune stimuli (treatment with 
lipopolysaccharide) (Crichton, 2006). Hepcidin is a negative regulator of iron 
uptake in the small intestine and of iron release from macrophages (Crichton, 
2006). In the absence of hepcidin, there is both increased absorption of dietary 
iron, leading to iron overload, and uncontrolled release of iron sequestered by 
macrophages, resulting in splenic iron deficiency (Crichton, 2006). In vitro studies 
have shown that interleukin-6 (IL-6) induces hepcidin during inflammation 
(Nemeth et al., 2004).  Plasma hepcidin binds ferroportin and blocks iron uptake 
from the duodenum and prevents iron release from macrophages (Crichton, 
2006). Not much is known about how hemojuvelin functions, but it appears its 
action involves the regulation of hepcidin expression (Crichton, 2006).  
 
Body iron losses are relatively small (1-2 mg per day), consisting of losses via 
epithelial cells (skin, gastrointestinal cells, urinary tract cells) and fluids (tears, 
sweat, and menstrual losses) (Miret, 2003).  These iron losses are distributed 
among gastrointestinal tract, skin, and urinary tract in a ratio of 6:3:1 (Crichton, 
2006).  For a 55-kg, non-menstruating woman, the basal iron loss would equal 
0.77 mg/day.  Menstruation increases the amount of iron loss, and absorption of 
1.36 mg of iron is the median requirement for maintenance of iron balance in 
normal menstruating women. To maintain balance in 95% of women, absorption 
of 2.84 mg/day of iron is required (Crichton, 2006). 
 17 
 
Figure  2.4: Effects of hepcidin on iron absorption and iron release from macrophages.  
Cornell University. http://diaglab.vet.cornell.edu/clinpath/modules/chem/femetb.htm 
 
 
 
 
The liver contains about 60% of the body‘s ferritin; the remaining 40% is found in 
muscle tissues and cells (macrophages) of the reticuloendothelial system 
(Crichton, 2006).  Theoretically, up to 4500 ferric iron atoms can be stored in one 
ferritin protein, and in-vivo, ferritin is normally about 20% saturated (800 iron sites 
occupied) (Beard, 2006).  The amount of ferritin synthesized by cells is under the 
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control of the mRNA-binding protein IRP, which binds with high affinity to an IRE 
located in the 5‘-untranslated end of ferritin mRNA.  A similar set of IREs exists 
on the 3‘ end of the mRNA for transferrin receptor and DMT-1 that allows 
reciprocal regulation of iron storage and iron uptake (Crichton, 2006).  In low iron 
situations, IRP1 binds to the IREs of various iron proteins to regulate the 
translation of the mRNA transcripts by stabilizing the mRNA and allowing 
translation of the peptide (Worwood, 2002). This results in an increase in the 
availability of erythrocyte free iron. The concentration of serum transferrin 
increases, but there is decreased saturation. In the presence of adequate cellular 
iron, binding of iron by IRP changes the conformation of the protein and prevents 
it from binding to the mRNA. The mRNA is quickly degraded and synthesis of 
transferrin receptors is reduced (Worwood, 2002). 
 
 
2.5 Iron Deficiency 
Iron deficiency is characterized by exhausted iron stores, which occurs when 
serum ferritin concentration drops below 12 µg/L. Simultaneous anemia (Hb<120 
g/L) leads to iron deficiency anemia. Clinical symptoms of iron deficiency include 
the signs and symptoms of anemia (tiredness and lassitude).  Clinical 
manifestations include glossitis, angular stomatitis, koilonchya (spooning of the 
nails), blue sclera, esophageal webbing, and microcytic hypochromic anemia 
(Beard, 2006).  Impaired immune function and responses, gastrointestinal 
abnormalities, changes in hair and nails, impaired thermogenesis and muscle 
function, altered thyroid metabolism, and changes in catecholamine turnover are 
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symptoms observed in patients with iron deficiency (Beard, 2006; Crichton, 
2006).  Iron deficiency also increases the risk of adverse pregnancy outcomes 
and impaired infant development (Zimmermann & Hurrell, 2007).  Iron deficiency 
is normally treated with an oral administration of 125 to 250 mg/day of ferrous 
sulfate, which should deliver 39 to 72 mg of elemental iron per day and will 
normally return a deficient person to normal iron levels within 12 weeks (Beard, 
2006). 
 
2.6 Assessment of Iron Status 
The best minimally invasive method of assessing iron status is measurement of 
serum ferritin concentration, which bears a quantitative relationship to iron stores 
in the range of 20 to 200 µg/L, with each 1 µg/L indicative of 8 mg of storage iron 
(Crichton, 2006).  A serum ferritin concentration of 12 µg/L indicates exhaustion 
of iron stores, and any values below this indicate depletion of the functional iron 
compartment.  Iron stores can also be invasively assessed by measuring the iron 
content of bone marrow, through liver biopsies or by quantitative phlebotomy. 
The gold standard for iron store estimation is staining a bone marrow aspirate for 
iron. 
 
Despite its usefulness in assessing iron status, ferritin is an acute-phase 
reactant, and as such it is elevated in states of infection, inflammation, neoplasia, 
hepatic dysfunction and alcohol consumption, resulting in misleadingly high 
serum ferritin concentration (Crichton, 2006). During an acute phase response, 
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acute phase proteins (APP) are produced prior to the full activation of the 
immune response to prevent tissue damage and to remove harmful molecules 
and pathogens.  Increased production of APP is due to changes in their 
production by hepatocytes, which are in turn regulated by cytokines such as 
interleukin-1, interleukin-6, and tumor necrosis factor alpha (Feelders et al, 
1998).  The APPs that are increased during inflammation include: C-reactive 
protein (CRP), alpha-1-antichymotrypsin (ACT), alpha-1-acid glycoprotein (AGP), 
serum amyloid A (SAA), fibrinogen, haptoglobin, ceruloplasmin and ferritin 
(Worwood, 2007). 
 
The major diagnostic challenge in the assessment of iron status is to differentiate 
between iron deficiency anemia in otherwise healthy individuals and anemia of 
chronic disease.  This is because inflammatory disorders tend to increase 
circulating hepcidin concentrations, and hepcidin blocks iron release from 
enterocytes and the reticuloendothelial system, resulting in iron-deficient 
erythropoiesis (Zimmermann & Hurrell, 2007).  The distinction between anemia 
of chronic disease and iron deficiency anemia is also difficult because increased 
serum ferritin in anemia does not rule out iron deficiency anemia in the presence 
of inflammation.  A commonly used marker of inflammation is C-reactive protein 
(CRP). However, the extent of increase of CRP concentration that invalidates the 
use of serum ferritin to diagnose iron deficiency is unclear, although CRP values 
higher than 10-30 mg/L have been used (Zimmermann & Hurrell, 2007). In our 
study we will use an hs-CRP cut-off value of 3mg/L to indicate inflammation. 
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Moreover, the increase in CRP during the acute-phase response is typically 
shorter in length than the increase in serum ferritin.  Alternative markers of 
inflammation include the alpha-1-acid glycoprotein (AGP) because it tends to 
increase later during infection than CRP and remains elevated for several weeks 
(Wieringa, 2002).  
 
Measurement of the soluble transferrin receptor (sTfR) in plasma may aid in 
distinguishing iron deficiency anemia from anemia of chronic disease.  This is 
because the main determinants of plasma sTfR are the erythroid mass in the 
bone marrow and iron status.  sTfR is derived mostly from developing RBCs and 
hence reflects the intensity of erythropoiesis and the demand for iron; the 
concentration rises in iron deficiency anemia and it is a marker of the severity of 
iron deficiency only when stores have been exhausted and erythropoiesis is 
increased, provided that there are no other causes of enhanced erythropoiesis 
(WHO, 2007; Cook, 2005; Skikne et al, 1990).  Also, plasma sTfR is not 
particularly affected by the acute-phase response, but it might be affected by 
malaria, age, and ethnicity (Cook, 2005; Verhoef et al, 2001; Menendez et al, 
2001) 
 
In developing countries, where there is a high frequency of infection, iron status 
assessment should include measures of plasma ferritin, whole blood hemoglobin 
as well as plasma sTfR (Mei, 2005).  When possible, additional measures such 
as whole blood zinc protoporphyrin (ZPP), plasma CRP, and/or AGP should also 
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be completed (Zimmermann, 2005).  In an anemic individual with high CRP, 
AGP, or both, high sTfR and ZPP concentrations are probably indicators of 
concurrent iron deficiency, despite high ferritin (Zimmermann and Hurrell, 2007).  
The WHO recommends that iron assessment include hemoglobin, serum ferritin 
and transferrin receptor, as well as at least one acute phase protein, with CRP, 
ACT and AGP as first choices (WHO, 2007). 
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CHAPTER 3 
 
IRON DEFICIENCY AS A PUBLIC HEALTH PROBLEM 
 
Iron deficiency is the most prevalent single nutrient deficiency in the world and is 
recognized by the World Health Organization (WHO) as 1 of the 10 greatest 
global health risks in existence today (WHO, 2002).  Iron deficiency is considered 
the primary cause of anemia, hence iron-deficiency anemia (IDA) and anemia 
are often used synonymously, and prevalence of anemia has often been used as 
proxy for IDA (WHO, 2008).  The WHO estimates the number of persons with 
anemia worldwide at almost 2 billion, with approximately 50% of the cases 
attributable to iron deficiency.  However, the prevalence varies according to 
population groups and local conditions (WHO/UNICEF/UNU, 2001). Despite the 
fact that iron deficiency is considered the primary cause of anemia, there are not 
enough data on the prevalence of iron deficiency, possibly due to the difficulty in 
assessing iron status with accuracy using a single indicator. Therefore, in order 
to acquire reliable information on existing iron deficiency, a combination of 
biomarkers must be used (WHO, 2008). 
 
Anemia is seldom present in isolation. It usually coexists with numerous other 
conditions, such as malaria, parasitic infections, nutritional deficiencies, and 
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hemoglobinopathies.  Risk factors for developing anemia include: low intake of 
iron, poor absorption of dietary iron from diets high in phytates or phenolic 
compounds (especially during periods of the life cycle when iron requirements 
are high), heavy blood loss (menstruation, delivery, or internal bleeding), 
parasitic infection (hookworm, ascaris, schistosomiasis), acute and chronic 
infection (malaria, cancer, tuberculosis, HIV), presence of other micronutrient 
deficiencies (vitamin A, vitamin B12, folate, riboflavin), and the impact of 
hemoglobinopathies (WHO, 2008). 
 
3.1 Epidemiology of Iron Deficiency 
Iron deficiency is a global public health problem, affecting both developed and 
developing countries with major consequences for human health as well as 
social and economic development.  It occurs in all stages of the life cycle, but the 
groups more susceptible to iron deficiency and anemia are preschool children, 
reproductive-aged women, and pregnant women.  According to the WHO, from a 
global perspective, the prevalence of anemia is highest in pre-school aged-
children (47.4%) and lowest in men (12.7%); however, the highest number of 
individuals affected is non-pregnant women (468.4 million) (WHO, 2008).  The 
prevalence and severity of iron deficiency is considerably greater in women than 
in men due to the physiologic requirements related to reproduction, such as 
menstruation, pregnancy, and lactation (Islam, 2001).  
The overall prevalence of anemia among women in developing countries is 42%, 
whereas in developed countries, the prevalence remains under 10% (WHO 
 25 
 
2008). Women are affected the most by anemia in South East Asia, where 200 
million women are anemic.  Of these, 182 million are non-pregnant women of 
reproductive age.  In Bangladesh, the estimated prevalence of anemia in 2001 in 
non-pregnant, non-lactating women from rural areas was approximately 33.2% 
(taken from random sampling); this translates to more than 11,000 women 
(WHO, 2008). 
 
3.2 Etiology of Iron Deficiency  
Iron deficiency can result from one or more of the following factors: inadequate 
dietary iron intake, poor absorption, and increased blood losses (Ma, 2007; 
Beard, 2006). Populations who have increased physiologic iron demands (i.e.: 
pregnant women and growing children) are at increased risk of not meeting their 
adequate iron intake. Diets high in phytates or phenolic compounds can inhibit 
iron absorption due to their ability to chelate and precipitate minerals (Ma, 2007). 
Increased blood losses, especially in menstruation and delivery for women, as 
well as gastrointestinal bleeding caused by parasitic infection such as hookworm 
and malaria can lead to iron depletion. Other nutrient deficiencies, such as 
vitamin A, folate, or vitamin B12, can lead to anemia.  
 
3.3 Iron Deficiency and Reproductive Health 
Iron deficiency and anemia can have a vast number of detrimental health effects, 
especially in at-risk populations, including preschool-aged children, pregnant 
women, and women of reproductive age (15-45.99 years). Women of 
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reproductive age naturally have increased iron needs that are related to 
menstruation, pregnancy and lactation.  Menstrual iron loss, estimated from an 
average blood loss of 33 mL/month, equals 1.5 mg of iron per day but may be as 
high as 2.1 mg per day (Cole et al. 1971).  There is also a higher demand for iron 
during pregnancy due to the increase in maternal red blood cell mass, growing 
fetal requirements (Allen, 1997) and to the compensation for blood losses during 
delivery. Some evidence suggests that pre-conception iron deficiency can 
influence the outcome of pregnancy. Mild and moderate anemia at pre-
conception have been associated with reduced fetal growth as well as increased 
risk of adverse pregnancy outcome in a cohort of Chinese women (Ronnenberg 
et al, 2004). 
 
Iron deficiency anemia during pregnancy is a risk factor for preterm delivery, 
subsequent low birth weight, and possibly inferior neonatal health (Allen, 2000).  
A direct causal relationship has not been established for the mechanism leading 
to these negative health outcomes, but it has been hypothesized that the 
resulting hypoxia from low iron status and anemia play a role in increasing stress 
hormones, norepinephrine, and cortisol during pregnancy, which can induce 
preterm labor (Allen, 2001). 
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CHAPTER 4 
 
ARSENIC 
 
Inorganic arsenic is a well- established human carcinogen that is associated with 
a myriad of adverse health effects in addition to cancer (National Research 
Council, 2001).  In the past decades, high levels of the element arsenic have 
been found in several water supplies in Southeast and Southwest Asia, South 
and Central America, and some areas in Africa.  Millions of persons are exposed 
globally through arsenic-contaminated drinking water. Light is being shed on the 
devastating effects of chronic arsenic poisoning as the signs and symptoms of 
arsenicosis are appearing.  There is also increasing evidence that susceptibility 
to the toxic effects may vary considerably among individuals and can depend on 
the concentration as well as duration of exposure. 
 
4.1 Arsenic: Properties 
Arsenic (As) is a widely-distributed metalloid found mainly in the earth‘s crust at 
an average concentration of 2 mg/kg (WHO, 2001).  It is usually present in trace 
amounts in all rock, soil, water, air, and biological tissues. Arsenic is present in 
over 200 mineral species, the most common of which is arsenopyrite or ferrous 
arsenic sulphide (FeAsS2); this form has been identified as the prime source of 
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arsenic pollution in Bangladesh (Fazal et al, 2001a).  Arsenic exists as inorganic 
and organic species.  It can be present in four electron valence states: -3, 0, +3 
and +5.  Inorganic arsenic has two main oxidation states: trivalent [arsenite, 
As(III)] and pentavalent [As(V), arsenate]. Arsenite is 60 times more toxic than 
arsenate (Fazal et al, 2001b).  
 
4.2 Arsenic Contamination 
Arsenic levels in groundwater average 1-2 micrograms/liter except in areas with 
volcanic rock and sulfide mineral deposits where arsenic levels can range up to 
3mg/liter (WHO, 2001).  Terrestrial plants may accumulate arsenic by root uptake 
from the soil or by adsorption of airborne arsenic deposited on the leaves (WHO, 
2001).  Non-occupational human exposure to arsenic from the environment is 
mainly via the ingestion of food and water.  In the case of Bangladesh, the 
population is mainly exposed through the intake of contaminated groundwater, 
which is used as drinking water; this arsenic is of geological origin. The WHO 
standard of arsenic in drinking water is 10µg/L, whereas the Bangladeshi 
standard for drinking water is much higher (50 µg/L) (Smith et al, 2000). The 
World Health Organization‘s provisional tolerable daily intake (PTDI) for arsenic 
is 2.1 µg As/kg-day (Kile et al 2007). 
 
4.3 Arsenic Metabolism 
Pentavalent and trivalent soluble arsenic compounds are extensively and rapidly 
absorbed in the gastrointestinal tract (WHO, 2001).  Arsenic metabolism is 
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usually characterized by two main types of reactions: (1) reduction reactions of 
pentavalent to trivalent arsenic, and (2) oxidative methylation reactions in which 
trivalent forms of arsenic are sequentially methylated to form mono-, di-, and 
trimethylated products with S-adenosyl methionine (SAM) as methyl donor and 
glutathione (GSH) as an essential co-factor (WHO,2001).  The methylation of 
inorganic arsenic facilitates its excretion in the form of dimethylarsinate (DMA(V)) 
and methylarsonate (MA(V)), which are readily excreted in urine (WHO, 2001; 
Vahter, 2002).  The trivalent arsenic compounds have been shown to be highly 
reactive and toxic (Petrick et al.,2000, Vega et al., 2001). 
  
 
 
 
Inorganic arsenic metabolism varies widely among species, populations and 
individuals.  Several factors appear to influence the metabolism of arsenic.  
Some studies suggest that genetic polymorphisms may have the strongest 
Figure 4.1: Metabolic pathway of arsenic metabolism in vertebrates. Abbreviations: GSH, 
glutathione; GST-omega, glutathione S-transferase omega; SAHC, S-ademosylhomocysteine; 
SAM, S-adenosylmethionine. Reproduced from Aposhian HV, Zakharyan RA, Avram MD, Sampayo-Reyes A, 
Wollenberg ML. 2004. A review of the enzymology of arsenic metabolism and a new potential role of hydrogen 
peroxide in the detoxification of the trivalent arsenic species. Toxicol Appl Pharcamol 198(3):327-335. 
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influence on rate and efficiency of inorganic arsenic methylation (Lindberg, 
2008). Previous studies have shown an association between malnutrition 
(particularly a protein-deficient diet) and higher risk for several arsenic-related 
toxic effects (Vahter et al, 1987), possibly due to alterations in arsenic 
metabolism or reduced antioxidant activity (Milton et al, 2004; Mitra et al, 2004).  
Several other nutritional factors also influence arsenic methylation, such as 
availability of methyl groups and micronutrients involved in one-carbon 
metabolism (Kile & Ronnenberg, 2008; Gamble et al, 2005).  Gender, age and 
smoking have also been shown to influence inorganic arsenic metabolism 
(Gamble et al., 2005; Loffredo et al., 2003; Steinmaus et al., 2005; Vahter, 2002). 
Lindberg suggests that sex hormones may enhance the efficiency of arsenic 
methylation in women of childbearing age (Lindberg et al, 2008). 
 
4.4 Arsenic Toxicity and Carcinogenicity 
Arsenic has the ability to impair cellular respiration by inhibiting various 
mitochondrial enzymes and uncoupling oxidative phosphorylation (Tchounwou, 
2003). Most arsenic toxicity results from its interaction with sulfhydryl groups of 
proteins and enzymes and its substitution for phosphorus in several biochemical 
reactions (Goyer, 1996).  In vitro, arsenic inhibits oxidation of pyruvate and beta-
oxidation of fatty acids by reacting with protein sulfhydryl groups to inactivate 
enzymes, such as dihydrolipoyl dehydrogenase and thiolase (Belton, 1985).  
Genotoxicity tests suggest that arsenic inhibits DNA repair and induces 
chromosomal aberrations, sister-chromatid exchanges, and micronuclei 
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formation in both human and rodent cell cultures as well as in cells from exposed 
humans (Tchounwou, 2003). Based on single-cell gel electrophoresis 
experiments (comet assay), arsenic trioxide induces DNA damage in human 
lymphocytes (Schaumloffel and Gebel, 1998).  In other studies, arsenic 
compounds have been noted to induce gene amplification, arrest cells in mitosis, 
inhibit DNA repair, and induce expression of the c-fos gene and the oxidative 
stress protein heme oxygenase in mammalian cells (Gonsebatt, 1997; 
Nakamuro, 1981; Natarajan, 1996; Ramirez 1997). 
 
As inorganic arsenic is metabolized, it is first methylated to (MMA(V)) and 
(DMA(V)).  Methylation of inorganic arsenic involves a two-electron reduction of 
pentavalent to trivalent arsenic species, followed by the transfer of a methyl 
group from a methyl donor.  The generally held view of arsenic carcinogenesis in 
the past was that arsenite (As(III)) was the most probable cause of 
carcinogenesis and the methylation of arsenic species was a detoxification 
pathway (Tchounwou, 2003). Several authors agreed that methylation minimized 
the toxicity or carcinogenicity of arsenic (Kitchin, 2001). A recent alternative view 
of arsenic carcinogenesis, however, is that there may be several forms of arsenic 
that  induce carcinogenesis and that arsenic methylation may be a toxification—
not a detoxification—pathway (Tchounwou, 2003).  (MMA(III)) has been found in 
urine of humans exposed to arsenic and this metabolite is known to inhibit 
enzymes and to cause cell toxicity and genotoxicity, and hence could be a 
potential cause of arsenic carcinogenesis (Tchounwou, 2003). 
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4.4.1 Possible Mechanisms of Arsenic Carcinogenesis 
Kitchin discusses nine possible modes of action of arsenic carcinogenesis in his 
review: induced chromosomal abnormalities, oxidative stress, altered DNA 
repair, altered DNA methylation patterns, altered growth factors, enhanced cell 
proliferation, promotion/progression, suppression of p53, and gene amplification 
(Kitchin, 2001).  Of these, three modes of action have shown positive results in 
both human and animal cell models: chromosomal abnormalities, oxidative 
stress, and altered growth factor (Tchounwou, 2003). The mode-of-action studies 
suggest that arsenic may be acting as a co-carcinogen, promoter, or a 
progressor of carcinogenesis (National Research Council, 2001). 
 
4.4.2 Animal Toxicity Studies 
To assess whether cytotoxicity and carcinogenicity of arsenic in animal models 
can be extrapolated to humans, it is necessary to have an understanding of the 
mode of action, metabolism, and toxicokinetics of different arsenic compounds in 
different animal species. Although a good animal model has yet to be found, rat 
and mouse models have been created for all human organs in which inorganic 
arsenic is known to cause cancer (skin, lung, urinary bladder, liver, and kidney) 
(Kitchin, 2001). 
 
During the methylation pathway, inorganic arsenic undergoes a series of 
reductions and oxidative methylations in the human body to form the pentavalent 
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species (which are more easily excreted in the urine) to highly reactive and 
unstable trivalent metabolites. These trivalent species are monomethylarsinous 
acid (MMAIII) and dimethylarsinous acid (DMAIII). Exogenous arsenic in the form 
of MMAV and DMAV shows limited absorption and metabolism in humans and 
most animals (except rats) and are excreted mostly as parent compound (Cohen 
& Arnold, 2006). The rat is considered a poor model for arsenic metabolism 
because it is the only known animal model where a large proportion of the DMA 
is bound to red blood cells, leading to a decreased urinary excretion of this 
compound and increased accumulation in the body (Vasken Aposhian et al. 
2004). 
 
Animal models for DMAV-induced promotion of carcinogenesis have been 
described for all five organs in which humans develop cancer post inorganic 
arsenic exposure; however, complete carcinogenesis by DMAV has only been 
achieved in rat bladder and mouse lung (Kitchin, 2001). Arsenic as a promoter of 
carcinogenesis (but not complete carcinogenesis) has been achieved in mouse 
models for skin and lung cancer and in rat models for bladder, kidney, liver, and 
thyroid cancer (Kitchin, 2001). Rossman et al. (2001) showed that arsenite 
(trivalent arsenic) is a co-carcinogen for mouse skin in the presence of solar 
ultraviolet radiation, but arsenite alone did not cause tumors (Rossman et al. 
2001). No carcinogenesis experiments have been reported with DMAV exposure 
in hamsters, dogs, or monkeys (species that do not develop tumors after 
inorganic arsenic administration) (Kitchin, 2001). Among mammals that 
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methylate arsenic, humans excrete unusually high amounts of MMA, thus human 
tissues may be exposed to higher concentrations of pentavalent or trivalent MMA 
than are mice, rats, beagles, hamsters, or rabbits (Vahter, 1994). 
 
4.4.3 Dietary influence on Arsenic toxicity 
A dietary supplementation and arsenic toxicity study in mice (Singh et al. 2008) 
showed that treatment with arsenic trioxide and jaggery for a month reduced the 
frequencies of clastogenic endpoints compared to arsenic-treatment alone. Garlic 
as well as the fruit Emblica officinalis, also have been shown to significantly 
reduce the clastogenicity caused by arsenic administration in mice 
(Roychoudhury et al, 1996; Choudhury et al. 1997; Biswas et al. 1999). Poddar 
demonstrated that dietary iron supplementation also helps prevent arsenic 
toxicity by reducing its clastogenic effects (Poddar et al. 2000); selenium has 
similar antagonistic properties as iron-arsenic affinity and can ameliorate the 
arsenic-induced mutagenicity and clastogenicity in mice (Biswas et al. 1995; 
Rossman et al. 2004).  A diet deficient in protein has been shown to decrease 
the arsenic methylation resulting in enhanced arsenic toxicity in rabbits (Vahter & 
Marafante, 1987). Other evidence indicates that oxidative stress is one of the 
major causes of arsenic toxicity. Studies in arsenic-exposed rats suggest that 
supplementation with vitamins E, C and A reduces the reactive species, helping 
reduce the toxic effects of arsenic (Wei et al. 2005; Ramanathan et al. 2005). 
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Figure 4.2: Arsenic-
induced plantar skin 
lesion. Dhaka Community 
Hospital, Bangladesh 
Arsenic Foundation 
4.5 Effects of Arsenic on Human Health 
Arsenic is known to be a human carcinogen. Several studies have suggested 
that arsenic toxicity in humans depends on the exposure dose, frequency and 
duration, age and gender as well as on individual susceptibility, which is 
influenced by genetic and nutritional factors (Chen & Lin, 1994).  Long-term 
exposure to arsenic increases the risk of cancer. In workers exposed to arsenic 
via inhalation, the main carcinogenic effect is an increase in their risk of lung 
cancer (Enterline & Henderson, 1987); when exposure occurs via ingestion, the 
main carcinogenic outcome is increased risk of skin cancer. In addition, chronic 
exposure to arsenic can result in increased risk of several 
internal cancers, such as liver, kidney, lung, colon, and 
bladder (Tchounwou et al, 1999).  Based on epidemiologic 
studies, chronic exposure to arsenic through contaminated 
drinking water also has non-carcinogenic effects on several 
organs and systems of the body including dermal, 
cardiovascular, reproductive, neurological, respiratory, 
hepatic, hematological, renal, and gastrointestinal 
(Tchounwou, 2003). 
 
Dermatologic effects: chronic arsenic exposure causes a characteristic pattern of 
noncarcinogenic dermal effects that starts with spots of hyperpigmentation and 
may progress to palmar and plantar hyperkeratosis (Mazumder, 1998). 
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Figure 4.3: Arsenic-
induced gangrene, (aka 
Blackfoot Disease).  
Dhaka Community Hospital, 
Bangladesh 
Arsenic Foundation 
These characteristic skin lesions induced by arsenic toxicity are used as an 
indicator of high exposure and are distinct from other clinical manifestations of 
arsenic toxicity (Tchounwou, 2003).  A study by Mazumder et al (1998) found 
that males were more likely than females to exhibit both hyperpigmentation and 
palmar-plantar keratosis.  
 
Cardiovascular Effects: Epidemiologic studies have 
shown that the cardiovascular system is especially 
sensitive to chronic exposure of arsenic contaminated 
drinking water. Some of the noticeable effects include 
hypertension and increased cardiovascular disease 
mortality. Rahman et al (1999) carried out a cross-
sectional evaluation of blood pressure in 1,595 adults 
over the age of 30 who lived all their lives in rural 
Bangladesh and were exposed to high arsenic 
levels. The study found that increasing arsenic 
levels in drinking water were associated with increased incidence and severity of 
hypertension. There is also an increased risk of coronary heart disease, as 
individuals with blackfoot disease have increased mortality from ischemic heart 
disease (Chen, 1988).  Blackfoot disease is a condition caused by peripheral 
atherosclerosis and thromboangiitis obliterans that results in gangrene and 
spontaneous amputation of the affected extremities (Tseng 1977). 
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Hematologic Effects and Diabetes:  Hernandez-Zavala et al studied the activities 
of enzymes of the heme biosynthesis pathway and their relationship with the 
profile of urinary protoporphyrin excretion in individuals exposed chronically to 
arsenic via drinking water in Mexico (Hernandez-Zavala et al, 1999).  The more 
evident alterations observed in heme metabolism of highly exposed individuals 
included increases in porphobilinogen deaminase (PBG-D) and 
uroporphyrinogen decarboxylase (URO-D) activities in peripheral blood 
erythrocytes; increases in the urinary excretion of total porphyrins, mainly due to 
coproporphyrin III (COPRO-III) and uroporphyrin III (UROIII); and increases in 
the COPRO/URO and COPRO-III/COPROI ratios (Hernandez-Zavala et al, 
1999). These results suggest that chronic arsenic exposure alters human heme 
metabolism. However, the biological mechanism responsible for these changes 
remains unknown. 
 
4.5.1 Effects of Arsenic on Female Reproductive Health 
Arsenic and its methylated metabolites have the ability to cross the placenta 
(Concha, 1998), and evidence from human studies suggests potential for 
adverse reproductive health effects.  Nordstrom et al. studied offspring of female 
employees and nearby residents of a Swedish copper smelter where high levels 
of arsenic were documented (Nordstrom et al, 1978a; Nordstrom et al, 1978b; 
Nordstrom et al, 1979a; Nordstrom et al, 1979b ). The offspring of women 
exposed to arsenic had lower birth weights than those of women who resided 
outside the smelter area, and the difference increased if the mothers worked in 
 38 
 
the jobs with increased exposure (Nordstrom et al, 1979b).  An incremental trend 
was noticed in the rates of spontaneous abortion with increasing exposure to 
arsenic (Nordstrom et al, 1978b; Nordstrom et al, 1979b).  Congenital 
malformations were also seen more frequently if the pregnant mother was 
employed in high-exposure jobs during gestation (Nordstrom et al, 1979a).   
 
Studies of populations affected by arsenic-contaminated drinking water have also 
found increased rates of spontaneous abortion and stillbirth (Borzsonyi et al. 
1992; Castro, 1982). A study in Inner Mongolia of a population exposed to 
arsenic-contaminated drinking water showed that even low arsenic levels in the 
water (20-50 µg/L) were associated with increased systolic blood pressure in 
women six weeks post partum (Kwok et al. 2007). It was suggested that the 
cardiovascular challenge during pregnancy increased arsenic susceptibility 
(Vahter, 2009).  There is also evidence that arsenic may cause anemia, 
especially during pregnancy, probably by destabilizing red blood cell  membranes 
(Biswas D et al. 2008) and decreasing delta-aminolevulinic acid dehydratase 
activity (Kannan GM et al, 2001), a critical factor in heme synthesis. 
 
4.5.2 Gender Differences in Arsenic toxicity: 
In general, women have a higher fraction of DMA and a lower fraction of MMA in 
urine than men (Hopenhayn-Rich, 1996).  This enhanced arsenic methylation in 
women has been shown to be limited to child-bearing age, since pre-pubertal 
and post-menopausal women showed methylation patterns similar to that of boys 
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and men, respectively (Lindberg, 2008).  This difference may be related to 
involvement of female sex hormones in the arsenic methylation process, which 
may influence endogenous production of choline in women. After its oxidation to 
betaine, choline is the only source of methyl groups, besides folate, for the re-
methylation of homocysteine to methionine (Vahter, 2009).  Choline is 
synthesized in the body by SAM-dependent methylation of serine or recycled 
from lecithin (phosphatidylcholine), whose synthesis was recently shown to be 
up-regulated by estrogen; this may explain the efficiency of arsenic methylation 
in women in women of reproductive age (Vahter, 2009). 
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CHAPTER 5 
 
BANGLADESH 
 
Bangladesh is located in Southern Asia, bordering the Bay of Bengal between 
Burma and India.  It comprises 144 thousand square kilometers, and is 
comparable in size to the U.S. state of Iowa (CIA, 2009).  The estimated 
population as of 2009 is 156 million, making Bangladesh the eighth most dense 
country in the world (CIA, 2009), with an estimated 2,000 inhabitants per square 
mile (UN, 1999); its capital city is Dhaka.  
 
The Bangladeshi population currently faces many public health challenges, one 
of the most important of which is arsenic poisoning.  The contamination of 
groundwater by arsenic in Bangladesh is the largest poisoning of a population in 
known history, with an estimated 35 to 77 million persons at risk of drinking 
contaminated water (Smith et al, 2000).  In the 1970s, the United Nation‘s 
Children‘s Fund (UNICEF) worked together with the Bangladeshi Department of 
Public Health to reduce morbidity and mortality from gastrointestinal diseases 
caused from drinking surface water contaminated with microbes and parasites.  
They installed tube wells that were 5-cm in diameter at a depth of less than 200 
meters to provide the Bangladeshi population with ―pure water‖ from 
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underground aquifers. At that time, arsenic contamination was not assumed to be 
a problem, and the water from these millions of wells was not tested for arsenic 
(Smith et al, 2000).  The problem of arsenic contamination became evident 20 
years later, when high arsenic levels were confirmed in 1993 upon testing the 
well water.  It was found that 43 out of the 64 districts of Bangladesh have 
arsenic levels higher than 50µg/L, which is the maximum level permitted or 
considered to be ―safe‖ in Bangladesh (Smith et al, 2000, Safiuddin, 2001); 59 
out of the 64 districts have arsenic levels higher than 10 ug/L, which is the 
maximum level recommended by the WHO (Hossain M.F., 2006). 
 
 
 
 
 
 
 
 
The Bangladeshi population exposed to these high levels of arsenic is at risk of 
developing arsenic poisoning, or arsenicosis.  Arsenicosis causes painful 
cutaneous skin lesions, such as keratosis, hyper- or hypopigmentation, whose 
latency is typically 10 years, although the appearance of these skin lesions is 
thought to be dose-dependent (Guha Mazumder DN et al., 1998; Tondel M, 
Rahman M et al, 1999).  Although the long-term effects of arsenic contamination 
 
Table 4.1: Magnitude of arsenic poisoning in Bangladesh  
 
Population of Bangladesh 125 million* 
Total population in regions where some wells are known to 
be contaminated: 
35-77 million 
Maximum concentration of arsenic permitted in drinking 
water according to WHO recommendations: 
 
10 µg/L 
Maximum concentration allowed in Bangladesh: 50 µg/L 
Number of tube wells sampled by the British Geological 
Survey (1998): 
2,022 
-Proportion of wells with arsenic concentrations >50 µg/L: 35% 
-Proportion of wells with arsenic concentrations >300 µg/L: 8.4% 
Smith A.H., Lingas E.O., & Rahman M. Contamination of drinking water by arsenic in Bangladesh: a 
public health emergency. Bulletin of the World Health Organization, 2000,78(9) 
 *Population of Bangladesh in year 2000 
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of drinking water appear to manifest slowly, which is why some of these negative 
health outcomes have only just begun to be observed, a great number of persons 
will develop these diseases in the future as a result of continuing exposure to 
arsenic. Currently there is an effort to determine whether nutritional status 
influences susceptibility to arsenicosis (Gamble et al. 2007; Milton et al. 2004; Li 
L. et al, 2008). 
 
Another important issue in Bangladesh is the quality of life, as determined by 
morbidity and poverty.  Close to 80% of the population lives in poverty, with a per 
capita income of $250 per year in the mid-1990s. Roughly 50% of the population 
survives on less than $1 per day, a percentage that is en route to being lowered 
to 30% in order to meet the Millennium Development Goals by 2015 (UN, 2005).  
The economy is based primarily on agriculture, and with the arsenic 
contamination issue, less land is able to be used, rendering the per hectare 
agricultural yield among the lowest in the world (Khuda Be & Helali J, 1991). 
  
Malnutrition in Bangladesh is also a challenging issue, as it relates to maternal 
health, pregnancy outcome and childhood development.  The cycle of maternal 
malnutrition, poverty, developmental delay and ill health all contribute greatly to a 
country‘s progress and economy.  The current proportion of Bangladeshi mothers 
who are malnourished is estimated at 45% (WHO, 2005). The proportion of births 
attended by skilled birth professionals has risen from 5% to 12% in the past few 
years, but still remains unacceptably low (WHO, 2005).  According to the WHO, 
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the maternal mortality ratio remains high at 570 deaths per 100,000 live births—a 
figure that is likely due in part to both malnutrition and arsenic exposure (WHO, 
2005). 
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CHAPTER 6 
 
PURPOSE OF THE STUDY 
 
Iron is an essential nutrient, especially in women of reproductive age, as it can 
heavily affect reproductive health and pregnancy outcome.  The female 
population of Bangladesh is likely at increased risk for iron deficiency, since there 
is a high prevalence of anemia. They are also at increased risk of arsenic toxicity 
in the drinking water.  Arsenic alters heme metabolism and erythrocyte function 
by binding to hemoglobin, changing the shape of erythrocytes (Delnomdedieu et 
al. 1995; Lu et al, 2004; Winski & Carter, 1995) and lowering hemoglobin levels 
(Flora et al 2005; Kannan et al, 2001). 
 
The effects of chronic arsenic toxicity on iron status remain largely unexplored.  
The main goal of this research project is to better understand the relationship 
between iron status, as measured by serum ferritin concentration, inflammation, 
and anemia in an arsenic-exposed cohort of reproductive-age women from 
Bangladesh.  The results from this study may lead to a greater understanding of 
the determinants of iron status in Bangladeshi women of reproductive age and 
may aid in the creation of interventions aimed at improving the iron status of this 
population.  The results from this study may also help to determine whether iron 
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status and inflammation status, as measured by hs-CRP, are affected by arsenic 
exposure.  
 
6.1 Hypotheses:  
 A large proportion of Bangladeshi women in this cohort will have depleted iron 
stores as determined by serum ferritin ≤12 micrograms/L. 
 A large proportion of anemia, as determine by Hb<120 g/L, will be related to 
iron depletion. 
 Although iron status may be compromised in women with arsenic-associated 
skin lesions (cases), inflammation will reduce our ability to detect iron 
depletion. 
 Increased serum concentration of hs-CRP, a marker of inflammation, will be 
more common among cases than controls. 
 
6.2 Specific Aims: 
1. Measure serum concentrations of ferritin and identify factors associated 
with ferritin levels among women of reproductive age from the Pabna 
district of Bangladesh. 
o Possible factors that will be analyzed include education and height, 
weight, and body mass index (BMI). 
2. Determine the percentage of women in this cohort with iron deficiency 
(ferritin ≤12 micrograms/L) and iron deficiency anemia (Hb <120 g/L and 
ferritin ≤12 micrograms/L). 
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3. Determine the percentages of cases and controls with elevated C-reactive 
protein (>3 mg/L) 
4. Assess the relationship between iron deficiency, inflammation, anemia 
and risk of arsenic-associated skin lesions. 
5. Determine whether C-reactive protein levels are useful in refining 
estimates of iron deficiency and iron deficiency anemia in women with and 
without arsenic-associated skin lesions. 
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CHAPTER 7 
 
MATERIALS AND METHODS 
 
7.1 Subjects 
Researchers in the Department of Environmental Health at the Harvard School of 
Public Health (HSPH) conducted a study focused on arsenic exposure and skin 
lesions in Bangladesh (Breton et al. 2006).  The study consisted of 1800 men 
and women (900 case-control pairs) recruited by Dhaka Community Hospital 
Trust primary-care clinics from 23 villages throughout the Pabna district of 
Bangladesh between 2001-2003. Up to 80% of controls from the initial HSPS 
study were selected from ―low-exposure‖ arsenic (<50 mcg/L) areas and 20% of 
the subjects were from ―high exposure‖ arsenic (≥ 50 mcg/L) areas in Pabna, 
based on the Bangladesh drinking water standard of 50 mcg/L. Participants with 
arsenic-induced skin lesions were only included in the study if a physician 
diagnosed any of the following: keratosis of the extremities; spotted melanosis; 
Bowen‘s disease; or squamous cell carcinoma.  Controls consisted of men and 
women from that same area without any visible signs of arsenic-induced skin 
lesions.  
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 The current research project included 147 women (75 cases, 72 controls) 
randomly chosen among female subjects 18 to 33 years of age who had serum 
archives of ≥ 1.3 mL.   
 
7.2 Data Collection 
At enrollment, anthropometric, behavioral and demographic data were obtained 
through a questionnaire administered by a community health worker. 
 
7.2.1 Blood Sample Collection  
Between 2001 and 2003, researchers from the Department of Environmental 
Health at the Harvard School of Public Health collected venous blood samples 
from all study subjects in Bangladesh. Hemoglobin was assayed from whole 
blood using Sahli’s method.  Serum was isolated by centrifugation, and aliquots 
were reserved, frozen and shipped on dry ice to HSPH where they were stored at 
-80◦ C.  Frozen serum samples from 147 women were transported on dry ice to 
the Ronnenberg laboratory at the Department of Nutrition, University of 
Massachusetts Amherst, where they were stored at -80oC until biomarker 
assessment. 
 
7.2.2 Laboratory Measurements 
Ferritin concentration was determined using a commercially-available enzyme 
immunoassay kit from Ramco Laboratories Inc (Stafford, TX). The immunoassay 
results were read by an MRX Microplate Reader (Revelation) at 490 nm 
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wavelength with a correction filter set at 520 nm wavelength.  In order to identify 
subjects who may have speciously elevated ferritin levels caused by infection or 
inflammation (and not sufficient iron status), high-sensitivity C-reactive protein 
(hs-CRP) levels were assessed using a commercially available immunoassay 
test kit from Biocheck, Inc (Foster City, CA).  This assay has been validated by 
numerous researchers (Vikram NK, et al. 2004; Elkind et al 2006). Hs-CRP 
concentrations were read using the same microplate reader mentioned above at 
a wavelength of 450nm. Both ferritin and hs-CRP levels were plotted against a 
standard curve to determine biomarker concentrations, which were calculated 
using GraphPad Prism version 4.00 for Windows (GraphPad Software, San 
Diego California, USA).  
 
Iron deficiency was defined as serum ferritin concentration equal to or below 12 
micrograms/liter.  Anemia was defined as hemoglobin levels under 120 grams/L, 
and iron-deficiency anemia was defined as hemoglobin under 120 grams/L and 
ferritin equal to or less than 12 micrograms/L. Iron deficiency in the presence of 
inflammation was defined as serum ferritin levels less than 50 micrograms/L if 
hs-CRP concentration exceeded 3mg/L.  
 
All participants provided informed consent, and the study protocol was approved 
by Human Subjects Committees of the Harvard School of Public Health and the 
University of Massachusetts Amherst. 
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7.3 Statistical Analyses  
The statistical analyses were carried out using SPSS version 16.0 (SPSS Inc., 
Chicago, IL, USA).  Descriptive data are presented as means +/- standard 
deviations, medians, ranges, and percentiles.  The normality of our variables was 
assessed using both Kolmogorov-Smirnov & the Shapiro-Wilk tests of normality.  
Natural log transformation was applied to variables that were not normally 
distributed (serum ferritin, hs-CRP, water arsenic & toenail arsenic). Geometric 
means and their 95% confidence intervals are presented for logarithmically 
transformed data. 
 
Physical and sociodemographic characteristics of the cases and controls were 
compared using the x2 test for categorical data and the student t-test for 
continuous data.  Simple linear regression and multivariable linear regression 
were performed to explore the relationship between serum ferritin and the same 
predictors mentioned above. Univariable and multivariable logistic regression 
models were used to explore the potential association between iron deficiency 
and the following potential predictors: age, height, weight, BMI, hs-CRP, toenail 
arsenic, water arsenic, education and marital status. Statistical significance was 
set at p < 0.05. 
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CHAPTER 8 
 
RESULTS 
 
Our study included 147 women from the Pabna district in Bangladesh. The 
demographic characteristics of the population by case-control status are 
presented in table 8.1. The women in this study ranged from 18-33 years in age. 
The mean height was 152 cm (4‘9‖) and weight was 102 pounds, resulting in an 
average BMI of 20.2 kg/m2. Almost a third (30%) of the women were classified as 
underweight with a BMI<18.5 kg/m2, and most of the remaining had a BMI 
between 18.5 kg/m2-25 kg/m2. The majority of the participants (73%) were 
married. Thirty-six percent of the study population had no formal education. This 
analysis cohort includes cases (N=75) and controls (N=72) based on the 
presence of arsenic-associated skin lesions (table 8.1). 
Because serum ferritin was not normally distributed according to the 
Kolmogorov-Smornov (p=0.000) and Shapiro-Wilk (p=0.00) tests of normality, 
data were transformed to their natural logarithm (ln). After ln transformation, the 
Kolmogorov-Smornov (p=0.2) showed a deviation from normality that was not 
significant, whereas the Shapiro-Wilk (p=0.03) test showed a significant deviation 
from normality in the log-transformed data. 
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Serum ferritin concentration ranged from 0.8 µg/L to 224.5 µg/L, with a geometric 
mean of 28.0 µg/L. Overall, 18.4% of the women had iron depletion (serum 
ferritin ≤12 µg/L). About a fifth of our sample had anemia (17.8%) as determined 
by hemoglobin <120 g/L (World Health Organization Standard).  
The main serological difference between women with arsenic-associated skin 
lesions (cases) and those without (controls) was the mean serum hemoglobin 
(124 g/L vs 129 g/L, respectively; p=0.02) as seen in table 8.1. Cases were also 
more likely to have inflammation (p= 0.04) and have a higher toenail arsenic 
concentration (p= 0.00).  
 
The proportion of women who had iron depletion was lower in women ages 28-
33 compared to those ages 18-22 years old (p=0.00). Married women were also 
less likely than unmarried women to have iron depletion (12.7% vs 35%, 
respectively; p=0.01). The prevalence of inflammation was 21.4%, as determined 
by high-sensitivity c-reactive protein levels over 3 mg/L (which was also log-
transformed). Women with normal serum ferritin levels were also more likely to 
have inflammation compared to those who were iron deplete; however, this was 
not statistically significant.  Over half of the study population‘s  main water source 
contained arsenic levels over the WHO health standard of 10 µg/L, and about a 
third (32.9%) of the participants‘ main water source contained arsenic levels over 
the safety standard for Bangladesh (>50µg/L). Arsenic data were also skewed 
and log transformed for our analysis (Table 1). 
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TABLE 8.1: Characteristics of Controls and Cases in our study 
Continuous 
Variables 
Mean ± SD 
(N=147) 
Controls (N=72) Cases (N=75) P-value 
(T-test) Mean ± SD Mean ± SD 
Age (years) 25.5 ± 5.0 25.7 ± 5.3 25.4 ± 4.74 0.66 
Height (cm) 152.0 ± 5.7 151.9 ± 6.0 152.1 ± 5.7 0.83 
Weight (kg) 47.2 ± 10.6 48.6 ± 13.2 46.0 ± 7.1  0.13 
BMI (kg/m2)c 20.2 ± 3 20.5 ± 3.0 19.9 ± 2.9 0.22 
Ferritin (µg/L)* 28.2 (24.2, 32.9) 27.8 (21.7, 33.0) 29.8 (23.9, 37.3) 0.48 
Hemoglobin (g/L)c 126.4 ± 12.8 128.9 ± 10.1 123.9 ± 14.5 0.02 
hs-CRP (mg/L)*c 0.7 (0.5, 1.0)  0.44 (0.23, 0.85) 1.0 (0.65, 1.7) 0.04 
Water As (µg/L)*c 15.3 (10.2, 23.0) 12.3 (7.6, 19.8) 18.9 (9.7, 36.9) 0.33 
Toenail As (µg/g)*c 2.5 (2.1, 3.0)  1.8 (1.5, 2.1) 3.5 (2.6, 4.8) 0.00 
Categorical 
Variables 
Total  
 N (%) 
Controls  
 N (%) 
Cases 
 N (%) 
P-value 
Age 
18-22 
23-27 
28-33 
 
50 (34) 
42 (28.6) 
55 (37.4) 
 
25 (50) 
18 (42.9) 
29 (52.7) 
 
25 (50) 
24 (57.1) 
26 (47.3) 
 
0.63 
BMI 
<18.5 kg/m2 
18.5-24.9 kg/m2 
>25 kg/m2 
 
44 (30.1) 
91 (62.3) 
11 (7.5) 
 
15 (34.1) 
50 (54.9) 
6 (54.5) 
 
29 (65.9) 
41 (45.) 
5 (45.5) 
 
0.07 
Iron status 
Normal ferritin 
Iron deplete (ferritin 
≤12ug/L) 
 
120 (81.6) 
27 (18.4) 
 
58 (48.3) 
14 (51.9) 
 
62 (51.7) 
13 (48.1) 
 
0.83 
Water Arsenic 
≤10 ug/L 
10-50 ug/L 
>50 ug/L 
 
60 (42.9) 
34 (24.3) 
46 (32.9) 
 
29 (48.3) 
24 (70.6) 
17 (37.0) 
 
31 (51.7) 
10 (29.4) 
29 (63.0) 
 
0.01 
hs-CRP (mg/L) 
Normal (<3 mg/L) 
High ( ≥3 mg/L) 
 
114 (78.6) 
31 (21.4) 
 
58 (50.9) 
13 (41.9) 
 
56 (49.1) 
18 (58.1) 
 
0.42 
Hemoglobin (g/L) 
Normal (Hb≥120 g/L) 
Anemia (Hb<120g/L) 
 
120 (82.2) 
26 (17.8) 
 
 64 (53.3) 
7 (26.9) 
 
56 (46.7) 
19 (73.1) 
 
0.02 
Marital Status 
Single/Unmarried 
Ever Married 
 
37 (25.2 
110 (74.8) 
 
18 (45.9) 
55 (50.0) 
 
19 (54.1) 
55 (50.0) 
 
0.83 
Education 
No formal education 
1ary or 2ary Education 
Higher secondary 
Educ. 
 
53 (36.1) 
69 (46.9) 
25 (17.0) 
 
23 (43.4) 
36 (52.2) 
13 (52.0) 
 
30 (56.6) 
33 (47.8) 
12 (48.0) 
 
0.60 
*presenting geometric means (exponentiated natural log mean values, and 95% CI) 
c
 missing one or more values: BMI: N=146 (controls:71), CRP:N=145 (controls:71; cases:74), Hb: N=146 (controls:71) 
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TABLE 8.2: Characteristics of Bangladeshi Women in our Study Sample  
(categorized by iron status) 
 
Continuous 
Variables 
 
Mean ± SD 
(N=147) 
Ferritin >12ug/L 
(N=120) 
Ferritin≤12ug/L 
(N=27) 
P-value 
(T-test) 
Mean ± SD Mean ± SD 
Age (years) 25.5 ± 5.0 26 ± 4.8 22 ± 4.8 0.001 
Height (cm) 152.0 ± 5.7 151.9 ± 5.8 152.2 ± 5.3 0.85 
Weight (kg) 47.2 ± 10.6 46.4 ± 7.5 46.8 ± 6.2 0.80 
BMI (kg/m2)c 20.2 ± 3 20.1 ± 3.06 20.2 ± 2.5 0.96 
Ferritin (ug/L)* 28.2 (24.2, 32.9) 38.7 (34.2, 43.7) 7.1 (5.5, 9.0) 0.000 
Hemoglobin (g/L)c 126.4 ± 12.8 126.5 ± 11.9 126.5 ±16.5 0.95 
hs-CRP (mg/L)*c 0.7 (0.5, 1.0) 0.9 0.6,1.3) 0.25 (0.1,0.8) 0.02 
Water As (ug/L)*c 15.3 (10.2, 23.0) 18.8 (12.0, 29.5) 6.2 (2.4, 15.9)  0.03 
Toenail As (ug/g)* c 2.5 (2.1, 3.0) 2.9 (2.3, 3.6) 1.4 (1.1, 1.8) 0.00 
Categorical 
Variables 
Total 
N (%) 
Ferritin >12ug/L 
N (%) 
Ferritin 
≤12ug/L N (%) 
P-value 
Age 
18-22 
23-27 
28-33 
 
50 (34) 
42 (28.6) 
55 (37.4) 
 
34 (68) 
35 (83.3) 
51 (92.7) 
 
16 (32) 
7 (16.7) 
4 (7.3) 
 
0.00 
BMI 
<18.5 kg/m2 
18.5-24.9 kg/m2 
>25 kg/m2 
 
44 (30.1) 
91 (62.3) 
11 (7.6) 
 
39 (88.6) 
71 (78.0) 
9 (81.8) 
 
5 (11.4) 
20 (22.0) 
2 (18.2) 
 
0.36 
Case Status 
Control 
Case 
 
72 (49) 
75 (51) 
 
58 (80.6) 
62 (82.7) 
 
14 (19.4) 
13 (17.3) 
 
0.83 
Water Arsenic 
≤10 ug/L 
10-50 ug/L 
>50 ug/L 
 
60 (42.9) 
34 (24.3) 
46 (32.9) 
 
45 (75.0) 
28 (82.4) 
41 (89.1) 
 
15 (25) 
6 (17.7) 
5 (10.9) 
 
0.18 
hs-CRP (mg/L) 
Normal (<3 mg/L) 
High ( ≥3 mg/L) 
 
114 (78.6) 
31 (21.4) 
 
89 (78.1) 
29 (93.5) 
 
25 (21.9) 
2 (6.5) 
 
0.07 
Hemoglobin (g/L) 
Normal (Hb≥120 
g/L) 
Anemia (Hb<120g/L) 
 
120 (82.2) 
26 (17.8) 
 
100 (83.3) 
19 (73.1) 
 
20 (16.7) 
7 (26.9) 
 
0.27 
Marital Status 
Unmarried 
Ever married 
 
37 (25.2) 
110(74.8) 
 
24 (64.9) 
96 (87.3) 
 
13 (35.1) 
14 (12.7) 
 
0.01 
Education 
No formal education 
1ary or 2ary Education 
Higher secondary 
Educ. 
 
53 (36.1) 
69 (46.9) 
25 (17.0) 
 
46 (86.8) 
56 (81.2) 
18 (72.0) 
 
7 (13.2) 
13 (18.8) 
7 (28) 
 
0.28 
 *presenting geometric means (exponentiated natural log mean values, and 95% CI) 
c
 missing one or more values (BMI: N=146, CRP:N=145, Hb: N=146, Water As: N=139, toenail As: N=139) 
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A summary of the dietary patterns of this cohort is shown in Table  8.3.  Low 
quality of the dietary data impeded us from carrying out further analysis in this 
dataset. 
Table 8.3 Dietary factors associated with Iron deficiency (serum ferritin ≤12 ug/L) 
Consumption 
frequency of each 
food: 
Total 
(N=147) 
Normal Iron status 
(ferritin >12ug/L) 
(%) 
Iron Depletion  
(ferritin ≤12ug/L) 
(%) 
p-value 
Fish: 
None to < 3/monthly 
1-6 times weekly 
Once or more per day 
 
4  
128 
15 
 
2 (50%) 
104 (81.3%) 
14 (93.3%) 
 
2 (50%) 
24 (18.8%) 
1 (6.7%) 
 
0.15 
Fowl: 
None/Almost none 
1-3/month 
1-6 weekly 
 
26 
105 
16 
 
19 (73.1%) 
88 (83.8%) 
13 (81.3%) 
 
7 (26.9%) 
17 (16.2%) 
3 (18.8%) 
 
0.43 
Beef : 
None/Almost none 
1-3/month 
1-6 weekly 
 
31 
92 
24 
 
24 (77.4%) 
77 (83.7%) 
19 (79.2%) 
 
7 (22.6%) 
15 (16.3%) 
5 (20.8%) 
 
0.62 
Egg : 
None/Almost none 
1-3/month 
1-6 weekly or 1-2 daily 
 
19 
48 
80 
 
16 (84.2%) 
37 (77.1%) 
67 (83.8%) 
 
3 (19.3%) 
11 (22.9%) 
13 (16.2%) 
 
0.63 
Bean : 
None/Almost none 
1-3/month to 1-6 weekly 
1 or more times daily 
 
135 
10 
2 
 
109 (80.7%) 
9 (90.0%) 
2 (100%) 
 
26 (19.3%) 
1 (10.0%) 
0 (0%) 
 
0.79 
Vegetables:  
None to <3/month 
1-6 weekly 
One or more daily 
 
8 
102 
37 
 
4 (50.0%) 
85 (83.3%) 
31 (83.8%) 
 
4 (50.0%) 
17 (16.7%) 
6 (16.2%) 
 
 
0.09 
Milk : 
None/Almost none 
1-3 times per month 
1-6/week to1-2/day 
 
30 
40 
77 
 
19 (63.3%) 
34 (85.0%) 
67 (87.0%) 
 
11 (36.7%) 
6 (15.0%) 
10 (13.0%) 
 
0.02 
Rice : 
None/Almost none 
1-3/month to 1-2/day 
3+ per day 
 
35 
27 
85 
 
34 (97.1%) 
22 (81.5%) 
64 (75.3%) 
 
1 (2.9%) 
5 (18.5%) 
21 (24.7%) 
 
0.01 
Bread : 
None/Almost none 
1-3/month to 1-2/day 
3 or more/day 
 
82 
36 
29 
 
61 (74.4%) 
31 (86.1%) 
28 (96.6%) 
 
21 (25.6%) 
5 (16.1%) 
1 (3.4%) 
 
0.02 
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We conducted univariable linear regression to evaluate the associations between 
potential covariates and (natural log) serum ferritin (table 8.4). Age, inflammation 
(hs-CRP), married status, toenail As and As in water were each significantly and 
positively associated with serum ferritin. In our multivariable linear regression, 
only hs-CRP (p=0.00), toenail arsenic levels (p=0.01) and marital status 
(p=0.001) were significant predictors of serum ferritin after adjustment for other 
variables.  
Table 8.4: Linear regression: predictors of  serum ferritin 
(Y=natural log of serum ferritin) 
 
 
 
Univariable 
Model 
 
Multivariable 
Model 1 
 
Multivariable 
Model 2 
  
Coefficient 
 
p-value 
 
Coefficient 
 
p-value 
 
Coefficient 
 
p-value 
Age (yrs) 0.04 0.004a 0.02 0.48   
Height (cm) -0.02 0.14a -0.02 0.21   
Hs-CRPc 0.12 0.000a 0.11 0.000b 0.11 0.000 
Toenail Asc 
(µg As/g toenail) 
0.22 0.002a 0.15 0.06b 0.16 0.017 
Arsenic  in water 
≤10ug/L 
10-50ug/L 
>50ug/L 
 
Ref 
0.22 
0.45 
 
 
0.27 
0.01a 
 
Ref 
0.13 
0.04 
 
 
0.52 
0.84 
  
Education 
No formal Educ. 
1ary or 2ary Educ. 
Higher 2ary Educ. 
 
Ref 
-0.25 
-0.49 
 
 
0.13 
0.03a 
 
Ref 
-0.05 
-0.12 
 
 
0.79 
0.68 
  
Marital Status 
Not Married 
Ever  married 
 
Ref 
0.71 
 
 
0.00a 
 
Ref 
0.40 
 
 
0.08b 
 
Ref 
0.55 
 
 
0.001 
a- Included in 1
st
 multivariable linear regression model (p-value <0.25) 
b- Included in 2
nd
 multivariable linear regression model (p-value <0.10) 
c- used transformed value (natural log transformation) 
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We used univariable logistic regression to identify factors crudely associated with 
iron depletion, defined as serum ferritin ≤12µg/L (table 8.5). From this analysis, 
we observed a strong association between increasing age and decreasing risk of 
iron depletion. Women in the oldest tertile were 81% less likely than women in 
the youngest tertile to have iron depletion (p=0.006). Marital status was also 
related to iron depletion (Table 8.6), as women who were married were 73% less 
likely to have iron depletion (p=0.003, 95%CI: 0.11, 0.65). Women in the highest 
tertile of toenail arsenic concentration were 84% less likely to have iron depletion 
(p=0.007) compared to those in the lowest tertile. Those whose water originated 
from wells containing the highest amounts of arsenic were 75% less likely to 
have iron depletion (p=0.015) compared to those whose water arsenic content 
was in the lowest tertile.  No other significant crude associations were observed 
in this analysis. 
 
From our multivariable logistic regression analysis in table 8.7, the only 
significant predictors of iron depletion were age, BMI, toenail arsenic, and 
inflammation after controlling for other variables. Women between 29-33yrs old 
were 84% less likely to have iron depletion compared to women ages 18-22 
(OR=0.16; 95%CI=0.04, 0.56). Women with inflammation were 80% less likely to 
have low ferritin compared to those without inflammation (OR=0.20, 95%CI=0.04, 
0.96). Women who were normal or over-weight (BMI>18.5kg/m2) were nearly 
four times more likely to have iron depletion (OR=3.72, 95%CI=1.17, 11.87) than 
were women with a lower BMI. In addition, r every 1µg As increase per gram of 
toenail was associated with a 45% lower risk of ID (OR=0.55, 95%CI=0.33, 0.94). 
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Table 8.5: Crude Associations with events of Iron Depletion (ferritin ≤12 µg/L),  
by tertiles 
 
 
 
N 
 
# events (%) 
 
OR 
 
95% CI 
 
p-value 
Age (years) 
18-22  
23-28  
29-33 
 
50 
48 
49 
 
16 (32) 
7 (14.6) 
4 (8.2) 
 
Ref 
0.36 
0.19 
 
 
0.13, 0.98 
0.06, 0.62 
 
 
0.046 
0.006 
Height (cm) 
<150  
151-154 
154-166 
 
56 
49 
42 
 
10 (17.9) 
11(22.5) 
6 (14.3) 
 
Ref 
1.33 
0.77 
 
 
0.51, 3.47 
0.26, 2.31 
 
 
0.56 
0.64 
Weight (lb) 
<97 
97.1-106 
106.1-156 
 
50 
48 
48 
 
8 (16) 
8 (16.7) 
11 (22.9) 
 
Ref 
1.08 
1.60 
 
 
0.37, 3.14 
0.58, 4.39 
 
 
0.895 
0.364 
BMI (kg/m2) 
<18.9 
18.9-20.6 
>20.6 
 
48 
49 
49 
 
7 (14.6) 
9 (18.4) 
11 (22.5) 
 
Ref 
1.35 
1.74 
 
 
0.46, 3.97 
0.61, 4.94 
 
 
0.585 
0.300 
CRP (mg/L) 
<0.5 
0.5-1.8 
1.8-51 
 
49 
48 
48 
 
12 (24.5) 
10 (20.8) 
5 (10.4) 
 
Ref 
0.79 
0.34 
 
 
0.30, 2.05 
0.11, 1.06 
 
 
0.63 
0.06 
Hb (g/L) 
<120  
121-130 
130-170 
 
53 
50 
43 
 
8 (5.1) 
10 (20) 
9 (20.1) 
 
Ref 
1.44 
1.52 
 
 
0.52, 3.99 
0.53, 4.35 
 
 
0.486 
0.433 
Toenail As (µg/g) 
0.1-1.3 
1.31-3.49 
3.5-53.75 
 
47 
48 
47 
 
14 (29.8) 
10 (20.8) 
3  (6.4) 
 
Ref 
0.62 
0.16 
 
 
0.24, 1.58 
0.04, 0.61 
 
 
0.32 
0.007 
As in water (µg/L) 
11-46 
47-94 
95-140 
 
46 
48 
48 
 
15 (32.6) 
6  (12.5) 
5  (10.4) 
 
Ref 
0.30 
0.25 
 
 
0.10, 0.85 
0.08, 0.77 
 
 
0.023 
0.015 
 
Table 8.6.Crude associations between socio-demographic factors and ID 
 N # events (%) OR 95% CI p-value 
Education 
No formal Education 
1ary/2ary Education 
Higher 2ary education 
 
53 
69 
25 
 
7 (13.2) 
13 (18.8) 
7 (28) 
 
Ref 
1.53 
2.56 
 
 
0.56, 4.14 
0.79, 8.3 
 
 
0.41 
0.12 
Marital Status 
Not married 
Ever Married 
 
37 
110 
 
13 (35.1) 
14 (12.7) 
 
Ref 
0.27 
 
 
0.11, 0.65 
 
 
0.003 
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Table 8.7:  logistic regression: predictors of  ID (Y=Iron Depletion) 
 Model 1 
(univariable) 
Model 2 
(includes p <0.25) 
Model 3 
(includes p<0.10) 
OR p-value OR p-value OR p-value (95% CI) 
Age 
18-22 
23-28 
29-33 
 
Ref 
0.36 
0.19 
 
 
0.046a 
0.006a 
 
Ref 
0.38 
0.16 
 
 
0.13 
0.02b 
 
Ref 
0.40 
0.16 
 
 
0.11 (0.13, 1.23) 
0.01(0.04, 0.56) 
Height (cm) 1.007 0.85     
Weight (kg) 0.99 0.80     
BMI (kg/m2) 
Underweight  
Normal weight/above 
 
Ref 
2.09 
 
 
0.17a 
 
Ref 
5.02 
 
 
0.01b 
 
Ref 
3.72 
 
 
0.03 (1.17, 11.87) 
Toenail As levels 
(µg/g)c 
0.48 0.005a 0.55 0.04b 0.55 0.03 (0.33, 0.94) 
Arsenic  in water 
≤10µg/L 
10-50µg/L 
>50µg/L 
 
Ref 
0.68 
0.39 
 
 
0.48 
0.09a 
 
Ref 
0.60 
0.66 
 
 
0.42 
0.53 
 
 
 
Hs-CRP 
No inflammation 
Inflammation 
 
Ref 
0.25 
 
 
0.07a 
 
Ref 
0.20 
 
 
0.06b 
 
Ref 
0.20 
 
 
0.05 (0.04, 0.96) 
Education 
No formal Education 
1ary or 2ary Educ 
Higher 2ary Educ 
 
0.7 
1.00 
1.7 
 
0.41 
 
0.34 
 
Ref 
0.60 
0.33 
 
 
0.45 
0.25 
  
Marital Status 
Not Married 
Married 
 
1.00 
0.31 
 
 
0.009a 
 
Ref 
0.35 
 
 
0.11 
  
a- Included in 1
st
 multivariable logistic regression model (p-value <0.25) 
b- Included in 2
nd
 multivariable logistic regression model (p-value <0.10) 
c- used transformed value (natural log transformation) 
 
Of the 147 women in the cohort, 26 had anemia (18%), as determined by the 
World Health Organization cutoff of hemoglobin levels less than 120 g/L (graph 
8.1).  The prevalence of iron depletion, as determined by serum ferritin <12 µg/L, 
was 18% (N=27) as observed in graph 8.2. 
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Cases have higher levels of inflammation, determined by serum c-reactive 
protein (p=0.04). The higher prevalence of inflammation in this group of women 
with arsenic-associated skin lesions could possibly mask iron depletion. In order 
to determine whether inflammation could be masking iron depletion, we extended 
the cutoff for ‗adequate‘ iron stores to 50µg ferritin/L in the presence of 
inflammation, defined as hs-CRP over 3 mg/L.   
ane
mia
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ane
mia
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controls ane
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Graph 8.2: Prevalence of iron deficiency in our study. ID, as defined by serum 
ferritin ≤12 ug/L, is 18% (N=27). The distribution of iron deficiency between controls 
and cases is similar, 19% (N=14) vs 17% (N=13), respectively. 
Graph 8.1: Prevalence of anemia in our study. Anemia, as defined by hemoglobin 
levels <120 g/L among this cohort is 18%. The difference in prevalence of anemia 
among controls and cases is statistically significant, with controls having a 
prevalence of anemia of 10% (N=7) vs 25% (N=19) in cases (p= 0.02) 
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The proportion of women who now had iron depletion increased from 18% 
(N=27) to 28% (N= 41) as observed in graph 8.3.  Among the 26 women with 
anemia (Graph 8.4), only 26% were also iron deficient (iron deficiency anemia). 
The prevalence of IDA did not change after the cut-off form iron deficiency was 
extended in the presence of inflammation (table 8.8).  The only predictor of 
anemia was case status (table 8.9; p=0.02). 
 
ID
28%
No 
ID
72%
controls
ID
28%
No 
ID
72%
cases
ID
28%
No 
ID
72%
total
63%
IDA
38%
controls
79%
IDA
21%
cases
ane
mia
74%
IDA
26%
total
Graph 8.4:  Prevalence of iron deficiency anemia. Among the women with anemia 
(N=26), the prevalence of anemia concurrent with iron depletion (Iron Deficiency 
Anemia, or IDA) varies by case-control status. Of the 7 controls with anemia, 38% 
(N=3) have IDA; of the 19 cases with anemia, 21% (N=4) have IDA. The total 
prevalence of IDA among the women with anemia is 26% (N=7). Total prevalence 
of IDA in this cohort is 4.8% (N=7) 
Graph 8.3: Prevalence of iron deficiency with inflammation. ID increases once 
inflammation is accounted for. The new cutoff for iron depletion (<50 ug/L if hs-crp 
>3mg/L) increases the proportion of women with iron depletion in both cases and 
controls. Controls increase from 19% (N=14) to 28% (N=20), and cases from 17% 
(N=13) to 28% (N=21). Total ID prevalence increases from 18% (N=27) to 28% 
(N=41). 
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Table 8.8: Proportion of women with Iron depletion using two different serum 
ferritin cutoff points to account for the presence of inflammation. 
 Controls (N=72) Cases (N=75) Total (N=147) 
Iron Depletion (ID) cutoff: 
Ferritin <12 ug/L 
Ferritin <50 ug/L (+ hs-CRP >3mg/) 
 
14 (51.9%) 
20 (48.8%) 
 
13 (48.1%) 
21 (51.2%) 
 
27 (18.4%) 
41 (28.3%)b 
Anemia (Hb<120g/L only) 7 (26.9%)a 19 (70.4%) 26 (17.7%) 
The following percentages are out of the total number of women with Anemia, as 
determined by Hemoglobin less than 120 g/L (N=26) 
IDA  (Hb<120g/L+ Iron depletion)  
Ferritin <12 ug/L 
Ferritin <50 ug/L (+ hs-CRP >3mg/) 
 
3 (42.9%) 
3 (42.9%) 
 
4 (57.1%) 
4 (57.1%) 
 
7 (26.9%) 
7 (26.9%) 
a
Controls included =71 
 
Table 8.9:  Logistic regression: predictors of  Anemia (Y=Hb<120g/L) 
 Model 1 
(univariable) 
Model 2 
(includes p <0.25) 
Model 3 
(includes p<0.10) 
OR p-value OR p-value OR p-value (95% CI) 
Age 
18-22 
23-28 
29-33 
 
Ref 
1.92 
1.23 
 
 
0.23* 
0.71 
 
Ref 
2.23 
1.69 
 
 
0.17 
0.39 
  
Height (cm) 0.97 0.49     
Weight (kg) 1.01 0.37     
BMI (kg/m2) 
Underweight  
Normal weight/above 
 
Ref 
1.19 
 
 
0.72 
    
Case Status 
Control 
Case 
 
Ref 
3.1 
 
 
0.02* 
 
Ref 
3.23 
 
 
0.02b 
 
Ref 
3.1 
 
 
0.02 (1.21, 7.92) 
Toenail As (µg/g) c 1.02 0.94     
Arsenic  in water 
≤10µg/L 
10-50µg/L 
>50µg/L 
 
Ref 
0.71 
0.60 
 
 
0.56 
0.35 
    
Iron status: 
Normal ferritin (>12ug/L) 
Low ferritin (<12ug/L) 
 
Ref 
1.8 
 
 
0.23a 
 
Ref 
2.4 
 
 
0.11 
  
Serum ferritin (ug/L)
C 
0.84 0.45     
Hs-CRP 
No inflammation 
Inflammation 
 
Ref 
0.78 
 
 
0.65 
    
Education 
No formal Education 
1
ary
 or 2
ary
 Educ 
Higher 2
ary 
Educ 
 
Ref 
0.59 
0.65 
 
 
0.27 
0.50 
    
Marital Status 
Not Married 
Married 
 
Ref 
1.53 
 
 
0.43 
    
c
-used transformed value (natural log transformation) 
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Table 8.10:  Logistic regression: predictors of Arsenic-associated skin lesions 
(Y=case/control status) 
 Model 1 
(univariable) 
Model 2 
(includes p <0.25) 
Model 3 
(includes p<0.10) 
OR p-value OR p-value OR p-value (95% CI) 
Age 
18-22 
23-28 
29-33 
 
Ref 
1.33 
0.90 
 
 
0.49 
0.78 
    
Height (cm) 1.006 0.83     
Weight (kg) 0.97 0.16a 1.01 0.86   
BMI (kg/m2) 
Underweight  
Normal weight/above 
 
Ref 
0.397 
 
 
0.015a 
 
Ref 
0.34 
 
 
0.05b 
 
Ref 
0.36 
 
 
0.02 (0.15, 0.86) 
Case Status 
Control 
Case 
 
 
     
Toenail As (µg/g)c 1.86 0.001a 2.29 0.001b 3.0 0.001 (1.43, 3.70) 
Arsenic  in water 
≤10µg/L 
10-50µg/L 
>50µg/L 
 
Ref 
0.39 
1.60 
 
 
0.04a 
0.24a 
 
Ref 
0.26 
0.97 
 
 
0.012b 
0.95 
 
Ref 
0.25 
0.95 
 
 
0.01 (0.09, 0.73) 
0.92 (0.35, 2.61) 
Anemia 
Hb>120g/L 
Hb<120g/L 
 
Ref 
3.10 
 
 
0.018a 
 
Ref 
7.12 
 
 
0.002b 
 
Ref 
7.13 
 
 
0.004 (2.09,24.3) 
Ferritin status 
Normal (>12ug/L) 
Low (<12ug/L) 
 
Ref 
0.87 
 
 
0.74 
    
Education 
No formal Education 
1ary or 2ary Educ 
Higher 2ary Educ 
 
Ref 
0.70 
0.71 
 
 
0.34 
0.48 
    
Marital Status 
Not Married 
Married 
 
Ref 
0.85 
 
 
0.67 
    
c
-used transformed value (natural log transformation) 
 
Higher toenail As levels (p=0.001) and anemia (p=0.00) were the two strongest 
predictors of arsenic-associated skin lesions after adjusting for other variables 
(table 8.10). 
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CHAPTER 9 
 
DISCUSSION 
 
Our study focused on young women of reproductive age from the District of 
Pabna in Bangladesh.  The prevalence of anemia in Bangladesh has been 
estimated by others to surpass 70% of the population, affecting approximately 
45% of the female, non-pregnant population (Ahmed, 2000). The prevalence of 
anemia, as determined by the WHO standard of less than 120 g/L, was much 
lower in our study group (17.8%). This could be in part due to the method of 
hemoglobin assessment used in the field, Sahli’s method. This colorimetric 
method of hemoglobin assessment has a potential for error rate due to subjective 
bias in visual comparison to determine concentration (Balasubramaniam  et al, 
1992). Sahli’s method has been found to have a high sensitivity (92.3% and 
98%), but a low specificity (39% and 66%) (Barduagniha et al, 2003; Anand et al, 
2009).  In our study population, there were 27 subjects whose hemoglobin 
concentration was exactly 120g/L, leading to our classifying them as not anemic. 
It remains unclear what proportion of these subjects were actually anemic, but 
had their hemoglobin levels rounded up to 120g/L, but had we included them in 
our anemic pool, the  estimated prevalence of anemia would have increased to 
36%. However, more recent studies have declared Sahli’s method to be in better 
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agreement [than other field hemoglobin tests] with autoanalyzer methods, which 
remain the gold standard for hemoglobin assessment (Anand et al, 2009). 
 
The WHO estimates that approximately half of the cases of anemia are due to 
iron deficiency. In our study, approximately one fourth (26.9%) of the subjects 
with anemia (N=26) had iron deficiency anemia (N=7), as defined by concurrent 
anemia (Hb<120g/L) and iron depletion (ferritin≤12µg/L). It has been assumed 
that half of the cases of anemia in developing countries are due to iron depletion, 
but we found this may not be the case in Bangladesh.  Ahmed found that severe 
anemia is less frequent in Bangladesh (2-3%); we did not find any subjects with 
hemoglobin levels less than 90 g/L, so this was in agreement with what is 
currently known (Ahmed, 2000).  However, according to the data on the etiology 
of anemia that Ahmed analyzed, iron deficiency seemed to be a substantial 
cause of anemia in the Bangladeshi population (Ahmed, 2000). This did not 
appear to be the case in our study population. Due to the nature of our study 
location, we adjusted the cut-off for defining iron depletion upward to account for 
the influence of inflammation or infection on ferritin, given that ferritin is an acute-
phase protein and infection may be more prevalent in Bangladesh. Bangladesh 
has high prevalence of communicable diseases, such as malaria (26 million 
people are at risk), tuberculosis (300,000 new cases per year), leprosy (Dhaka 
still has some cases of leprosy), and filiariasis, which is a problem in the northern 
districts of Bangladesh (WHO, 2010). Previous studies have extended the normal 
12-15 µg ferritin/L cutoff to 30-50µg/L to account for infection or inflammation 
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(Beard et al, 2006). We categorized those women who had ferritin levels <50µg/L 
in the presence of inflammation (hs-CRP >3mg/L) as iron depleted. This resulted 
in an increased sensitivity for diagnosing iron depletion, at the cost of possible 
decreased specificity. The new cut-off increased our number of iron depleted 
women from 27 to 41 (18.4% to 28.3%), but the prevalence of IDA remained the 
same. 
 
The strongest predictors of serum ferritin levels were serum c-reactive protein 
(p=0.000), marital status (p=0.001) and toenail arsenic levels (p=0.02). Ferritin, 
being an acute-phase reactant, is elevated in states of infection, inflammation, 
neoplasia, hepatic dysfunction and alcohol consumption (Crichton, 2006). 
Therefore the observation of an association between the marker of inflammation, 
c-reactive protein, and serum ferritin was not surprising. The average age for 
married women in our study was 27 years, whereas unmarried women were 20.9 
years old. We observed a significant decrease in risk of iron deficiency as women 
grew older;  women who were in the oldest group (ages 29-33) were 84% less 
likely to have iron depletion compared to the youngest group (ages 18-22) 
(p=0.01). Hence, the association with marital status is most likely due to the 
difference in age.  
 
The association between toenail arsenic concentration and serum ferritin levels 
was unexpected. Women who had normal iron stores (serum ferritin>12µg/L) had 
twice the toenail arsenic concentration of those who were iron depleted (2.9 µg 
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arsenic/gram toenail compared to 1.4 µg arsenic/gram toenail) (p=0.00). This 
observation could be due to the presence of high levels of iron in the same 
tubewell water where arsenic is prevalent. The national hydro-chemical survey of 
groundwater conducted by the British Geological Survey (BGS) and the 
Department of Public Health Engineering (DPHE) in Bangladesh have shown 
that a large proportion of wells exceed permissible limits for both iron and arsenic 
(BGS, DPHE, 2001). The permissible limit of iron for drinking water is 300µg/L to 
1.0mg/L, but in Bangladesh, Hossain reported that 41% and 25% of the 
tubewells studied exceeded iron concentrations of 1.0mg/L and 5.0 mg/L, 
respectively (Hossain et al, 1997).  In the district of Dhaka, the correlation 
between arsenic and iron concentrations was significant with a correlation 
coefficient of 0.47 p =0.0001 (Tonmoy et al, 2009). We found that the mean 
arsenic content (µg/L) in the tubewell water of women with normal ferritin levels 
was three times higher than the tubewell water of women who were iron deplete 
(18.8 µg arsenic /L compared to 6.2 µg arsenic/L, p=0.03). However, arsenic 
water concentration was not a predictor of iron status. A possible explanation for 
the absence of association could be the lack of water consumption or usage 
data. The food frequency questionnaire used to collect the dietary data did not 
include water intake. 
 
We did not observe any significant associations between dietary factors and iron 
status or arsenic toxicity. However, there was a slight trend toward decreased 
iron deficiency among women who consumed more fish, fowl and beef compared 
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to those who consumed less of these animal foods. According to Kile et al, the 
dominant source of arsenic exposure in women living in Pabna is the water 
consumed (Kile et al, 2007). They also observed that as arsenic concentrations 
in the drinking water decrease, the relative contribution of dietary arsenic sources 
are more relevant to ingested doses. Therefore, the combined intake from both 
diet and drinking water can result in arsenic consumption that exceeds the 
WHO‘s provisional tolerable daily intake of 2.1 pg As/kg-day, despite using tube 
well that contains less than 50µg As/L (Kile et al, 2007). 
 
In our study population, we also had 75 subjects with As-associated skin lesions 
(cases) and 71 without skin lesions (controls).  The women with As-associated 
skin lesions had a slightly higher mean serum ferritin concentration, but this was 
not significant (27.8 µg/L compared to 29.8 µg/L, p=0.48). However, the mean c-
reactive protein concentration was significantly higher in cases (1.0 mg/L) 
compared to controls (0.44 mg/L) (p=0.04). This could be caused by possible 
gastrointestinal and hepatic effects of chronic arsenic consumption, which could 
lead to inflammation and necrosis of the mucosa and submucosa of the stomach 
and intestine or cirrhotic portal hypertension (ATSDR 2007; Datta 1976).  
Experimental studies have also shown that arsenic exposure can inhibit 
endothelial nitric oxide synthase and produce inflammation and changes in 
coagulation, contributing to atherosclerosis (Simeonova and Luster, 2004). Case 
subjects also used tubewell water with a mean arsenic concentration that was 
1.5 times higher than the water used by the controls (18.9 µg As/L compared to 
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12.3 µg As/L for controls; p=0.33) and had much higher As toenail levels 
compared to controls (3.5 µg As/gram toenail vs 1.8 µg As/ gram toenail; 
p=0.00). There was a significant trend among subjects who used water with the 
highest As level and As-associated skin lesions. Of the 46 subjects that used 
tubewell water with As levels higher than the Bangladeshi safety standard (>50 
µg As/L) 63% were cases and 37% were controls (p=0.01). Case subjects were 
also more likely to have anemia (p=0.02), but not iron depletion (p=0.83). Breton 
et al found that higher hemoglobin levels were significantly protective against the 
presence of skin lesions in males, but not in Bangladeshi females (Breton et al. 
2006). In our study, we found that women with As-associated skin lesions were 3 
times more likely to have anemia (p=0.02) and vice-versa--women with anemia 
were 5.7 times more likely to have As-associated skin lesions (p=0.004).  
 
The etiology of much of the anemia in our study population does not appear to be 
related to iron status, contrary to our expectations. Another possible cause of 
anemia could be deficiency of other nutritional factors that play a role in arsenic 
metabolism.  Inadequate intakes of folate, methionine, calories, or protein are 
associated with arsenic-related health effects in both humans and animals 
(Vahter and Marafante, 1987; Hoffman et al, 1992; Lammon and Hood, 2004; 
Mitra el at , 2004; Chen et al, 1988). Other nutrients involved in one-carbon 
metabolism have been associated with the presence of skin lesions or with 
change in urinary arsenic species (Mitra et al, 2004; Steinmaus et al, 2005). 
Dietary factors that are related to one-carbon metabolism include folate, 
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methionine, cysteine, choline, betaine, and vitamins B6 and B12 (Gamble et al, 
2007). Gamble et al found that urinary DMA was positively associated with 
plasma folate, and negatively associated with homocysteine; they also found that 
inorganic arsenic and MMA were negatively correlated to plasma folate levels 
(Gamble et al, 2005).  
 
Folate and other nutrients directly linked to one-carbon metabolism may be 
directly linked to the anemia found in our study population, as the prevalence of 
hyperhomocysteinemia is reportedly high in this area, indicating the folate in this 
population may be compromised, possibly resulting in megaloblastic anemia, 
rather than iron deficiency anemia (ACC/SNC, 2001). Additional blood 
parameters, such as the mean cell volume (MCV), would be helpful in 
distinguishing among the causes of anemia. 
 
9.1 Strengths and Limitations 
An important strength of our current study is that our population was 
homogeneous in terms of race, and age was evenly distributed across cases and 
controls. We also used toenail arsenic levels as a marker of long-term arsenic 
exposure.  This is the first study that examines the etiology of anemia in the 
population of Bangladeshi women of reproductive age using serum ferritin in 
addition to hs-CRP to account for inflammation. 
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Our main limitation is the limited amount of serum volume we received, which 
precluded assessment of other biomarkers, such as folate, vitamin B12 and 
transferrin receptor. It would have been ideal to include transferrin receptor as 
one of our assessment tools for iron status, since this biomarker is reflective of 
iron stores and is not affected by infection or inflammation. These two conditions 
can be significant interfering factors in Bangladesh due to its high prevalence of 
communicable diseases. Although elevated CRP can identify some persons with 
inflammation, it has a faster spike than ferritin and a shorter half-life, so we may 
not have been able to identify all women who were actually iron deficient despite 
―normal‖ ferritin as a result of inflammation. . 
 
Lack of quality dietary data is also a weakness, as we were not able to fully 
assess the relationship between food intake and iron status or arsenic toxicity. 
Due to lack of health data, such as parity, menstrual characteristics, infections 
we were not able to fully explore female-related factors that can influence iron 
status in this population, leaving room for potential residual confounding.  
 
9.2 Future Directions 
In order to test the validity of our conclusions, the next steps would include 
assessing plasma folate and vitamin B12, in addition to observing the size of the 
red blood cells in the subjects with anemia (but not iron deficiency). Assessing 
hemoglobin from whole blood would be useful to get a more accurate 
assessment of their hemoglobin (anemia) status as well. Measuring transferrin 
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receptor would be the ideal step to get a more accurate determination of the 
prevalence of iron depletion in the presence of inflammation. 
 
 It would also be helpful to have more detailed dietary data, including water 
consumption and use (both frequency and duration of water use) to determine 
the extent to which whether arsenic toxicity results from exposure via water or 
food.  Finally, assessment of water iron in addition to arsenic content from the 
tubewells where the subjects get their water would help to confirm whether 
drinking water helps protect against iron deficiency.  
 
9.3 Conclusion 
The prevalence of anemia was much lower than expected (18%) compared to 
previous estimates of 45% for the Bangladeshi female non-pregnant population 
and over 70% for the overall population (WHO, 2008; Ahmed, 2000). The 
prevalence of IDA was 4.8%. Women with As-associated skin lesions were more 
likely to have anemia, but not ID, compared to controls. The proportion of women 
with ID was much lower than expected (18%); however, once inflammation was 
accounted for, the prevalence increased to 28%. Women exposed to higher 
levels of water arsenic and those with higher toenail arsenic concentrations were 
less likely to have iron depletion.  A possible explanation for this association 
could be the moderately strong correlation between arsenic and iron found in the 
tubewell water near our study region. It appears that a large proportion of the 
anemia observed in this population may be due to inadequacy of other 
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micronutrients, such as folate and B12, which are needed in both hematopoiesis 
as well as arsenic metabolism. Further studies are needed to determine the 
folate and B12 status in women of reproductive age in Bangladesh, as these 
nutrients, which are also key players in pregnancy and reproductive health, may 
be compromised due to arsenic exposure. 
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